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Abstract
Drug delivery systems have gained significant interest in the pharmaceutical industry for the
treatment of various diseases, such as cancer, neurological and genetic disorders, and viral
infections. While many of the designed compounds show great potential by having a high affinity
to their specific molecular targets in vitro, their potency is limited due to their failure to deliver
molecules across the cell membrane. Their transporting ability is affected by their characteristics
such as poor water solubility, charge, hydrophobicity, and size. Thus, there is a necessity for the
design of new molecular transporters that can efficiently deliver molecules across the semipermeable plasma membrane. Peptides have been studied rigorously as a drug delivery system due
to several factors such as their capability to bind specific cell surface receptors, their ability to
permeate through the hydrophobic core of the plasma membrane, and the ease of making small
adjustments to the amino acid sequence. Furthermore, the major concern of targeting of a single
molecular marker of the cancerous cell is tumor heterogeneity and rapid mutations. It is vital to
focus on an intrinsic property of the diseased cell, such as the extracellular pH of cancer cells. For
example, in malignant tumors, the extracellular pH can approximately be one pH unit lower than
normal cells. A pH-triggered membrane peptide can be used to target cells with altered
extracellular pH. Therefore, we have designed the acidity triggered rational membrane (ATRAM)
peptide as a novel class of pH-sensitive peptides to address these applications. Here we established
that the ATRAM peptide interacts in a pH-sensitive manner with membranes of liposomes and
cultured cancer cells. ATRAM also interacts reversibly with human serum albumin suggesting
that while the peptide can use albumin as a carrier in the blood stream, explaining its ability to
avoid immediate proteolysis in vivo, it will still target and transfer to the cell membrane. Moreover,
we tried to fine-tune the pH responsiveness of ATRAM. The subsequent single N-terminal
modifications to the peptide sequence resulted in diverse interactions with cancer-mimic lipid
vesicles.

v

Table of Contents
Chapter I. Introduction .................................................................................................................................. 1
1.1. Prevalent problems with current anticancer drugs ............................................................................. 2
1.2. Targeted cancer therapy ..................................................................................................................... 4
1.3. Characteristics of cancer cells ............................................................................................................ 5
1.4. Peptides as cancer therapeutics .......................................................................................................... 8
1.4.1 Antimicrobial peptides ................................................................................................................. 8
1.4.2 Cell Penetrating peptides ........................................................................................................... 10
1.4.3 Tumor Targeting Peptides (TTP) ............................................................................................... 11
1.4.4 Summarized advantages and disadvantages............................................................................... 12
1.5. pH responsive peptides .................................................................................................................... 12
1.5.1 TMX........................................................................................................................................... 13
1.5.2 LAH4 ......................................................................................................................................... 14
1.5.3 pHD Peptides ............................................................................................................................. 14
1.5.4 pH-Switchable Pore Formation Peptides ................................................................................... 15
1.5.5 AMP Derived pH-Responsive Peptide....................................................................................... 16
1.5.6 Cyclic pH-Responsive Peptide................................................................................................... 16
1.5.7 GALA ........................................................................................................................................ 17
1.5.8 pH-Low Insertion Peptides ........................................................................................................ 17
1.6. Serum albumin as a carrier in the bloodstream ................................................................................ 20
1.7. Summary of conducted work ........................................................................................................... 20
Chapter II. A novel soluble peptide with pH-responsive membrane insertion ........................................... 22
2.1. Abstract ............................................................................................................................................ 24
2.2. Introduction ...................................................................................................................................... 25
2.3. Experimental Procedures ................................................................................................................. 25
2.4. Results .............................................................................................................................................. 30
2.5. Discussion ........................................................................................................................................ 39
Chapter III. Mechanistic insights into the pH-dependent membrane peptide ATRAM ............................. 45
3.1. Abstract ............................................................................................................................................ 47
3.2. Introduction ...................................................................................................................................... 48
3.3. Experimental Procedures ................................................................................................................. 50
3.4. Results .............................................................................................................................................. 61
3.5. Discussion ........................................................................................................................................ 82
vi

Chapter IV. The effect of phosphatidylserine on a pH-responsive peptide is compounded by its noninserting end ................................................................................................................................................ 91
4.1. Abstract ............................................................................................................................................ 92
4.2. Introduction ...................................................................................................................................... 93
4.3. Experimental Procedures ................................................................................................................. 94
4.4. Results ............................................................................................................................................ 100
4.5. Discussion ...................................................................................................................................... 114
Chapter V. Conclusions and Future Directions ........................................................................................ 121
5.1. Conclusions .................................................................................................................................... 122
5.2. Future Directions ........................................................................................................................... 124
References ................................................................................................................................................. 125
Vita............................................................................................................................................................ 140

vii

List of Tables
Table 1. Peptide Sequences .......................................................................................................... 9
Table 2. Sequences of peptides used .......................................................................................... 52
Table 3. Stopped-flow rate constants and amplitudes ............................................................. 68
Table 4. Sequences of the ATRAM peptide and the variants ................................................. 96
Table 5. Fluorescence spectral maxima of the acidic and basic baselines ........................... 102

viii

List of Figures
Figure 1. Characteristics of cancer cells. .................................................................................... 7
Figure 2. Representation of the three different states of pHLIP. ........................................... 19
Figure 3. Biophysical characterization of the ATRAM peptide. ............................................ 33
Figure 4. Membrane interaction of the ATRAM peptide. ...................................................... 35
Figure 5. Self-assembly of the ATRAM peptide. ..................................................................... 37
Figure 6. pH-dependent interaction of ATRAM with cells. .................................................... 38
Figure 7. Zeta potential and size analysis. ................................................................................ 53
Figure 8. Membrane orientation of ATRAM insertion in cells. ............................................. 62
Figure 9. Membrane orientation of ATRAM insertion in cells. ............................................. 64
Figure 10. Kinetics of ATRAM-NBD insertion in POPC bilayers. ........................................ 65
Figure 11. Averaged stopped-flow spectra of ATRAM in POPC. .......................................... 66
Figure 12. ATRAM concentration affects POPC membrane disruption. ............................. 69
Figure 13. Peptide concentration affects the adsorption of ATRAM to POPC vesicles....... 71
Figure 14. Representative fluorescence emission spectra of ATRAM-NBD. ........................ 72
Figure 15. ATRAM concentration does not affect the insertion pK into POPC vesicles. .... 74
Figure 16. Lipid membranes compete with human serum albumin for ATRAM binding. . 75
Figure 17. Y-ATRAM-BODIPY binds to cells in a pH dependent fashion. .......................... 78
Figure 18. Distribution of 125I-ATRAM mice. .......................................................................... 79
Figure 19. Microautoradiographs of tissue from WT mice ................................................... 81
Figure 20. Serum stability of ATRAM conjugated with NBD. ............................................... 83
Figure 21 The peptides interact with the lipid membrane in a pH dependent manner. .... 101
Figure 22. The peptides changed in secondary structure in a pH dependent manner. ...... 103
Figure 23. The ATRAM peptides adopt a TM conformation at low pH. ............................ 105
Figure 24. Representative pH titration curves of ATRAM and the variants. ..................... 106
Figure 25. The effect of POPS and NaCl on the pKFI of ATRAM and the variants........... 107
Figure 26. Representative pH titration curves of ATRAM and the variants. ..................... 108
Figure 27. Overlay of pH titration of ATRAM in POPC vesicles ........................................ 110
Figure 28. Kp of ATRAM and the variants. ........................................................................... 111
Figure 29. The effect of POPS on the Kp of ATRAM and the variants. .............................. 112
Figure 30. Representative binding isotherms ......................................................................... 113
Figure 31. Membrane leakage studies. .................................................................................... 115
Figure 32. Schematic of the surface-bound state of the ATRAM peptides. ........................ 118

ix

Chapter I. Introduction
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1.1. Prevalent problems with current anticancer drugs
Some of the most promising anticancer drug candidates are also the most hydrophobic. While
these anticancer drugs show great potential in vitro, their use in clinical trials has been less than
unsuccessful due to low solubility and off-target side effects (1-3). Most of the drugs are either
weakly acidic or weakly basic, resulting in poor aqueous solubility (4). The low solubility in
aqueous media reduces the clinical utility of the drug due to low bioavailability and, consequently,
suboptimal drug concentrations at the site of action. Bioavailability is a measure of absorption and
represents the portion of the administered dose to enter the vascular system to access the site of
action (4).

Less water-soluble drugs need increased doses in order to reach therapeutic

concentrations at the site of action. Hydrophobic drugs therefore require solubilizing agents,
which are mostly organic solvents, in order to be able to be absorbed by cancer cells. (5, 6).
However, these solubilizing agents not only reduce the potency of the drugs but also may have
undesirable toxic side effects such as causing hypersensitivity, neurotoxicity, and nephrotoxicity
(5).
Camptothecin, doxorubicin, and paclitaxel are successful anticancer drugs (7). While in vitro
studies have shown that these drugs are effective against different cancers, such as breast, bladder,
melanoma, and lung, they require mixing with solubilizing agents, such as a mixture of the
detergent Tween 80 or Kolliphor EL (a castor oil derivative formerly known as Cremophor EL),
and ethanol, in order to be used in humans. Such formulation results in decreased potency of the
drug and increased toxic side effects (5), which limit the efficacy of these and many other
anticancer drugs. For instance, doxorubicin is a widely used chemotherapeutic; however, besides
the adverse effects of nausea, alopecia and neutropenia, its dose-dependent cardiotoxicity limits
the drug’s clinical usage (8). All these effects are the result of different mechanisms, such as the
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immune system being hyper-activated, reduced progenitor cell repair, and inhibition of growth
factors. The main mechanism for the cardiotoxicity is believed to be due to iron oxidation and
oxygen free radical generation (8). Peripheral nerves can also be affected by commonly used
chemotherapeutic agents (9, 10). Paresthesia, loss of sensory function, and neuropathic pain can
result from use of these cytotoxic drugs. In the case of paclitaxel, neurotoxic side effects can be
dose-limiting (11). Paclitaxel stabilizes microtubules, which consequently arrests mitosis and
leads ultimately to cell death. However, neurons are also prone to being affected by the drug. The
loss of microtubule dynamic instability is thought to be the cause for the toxicity to microtubulerich axons (11, 12). Another important limitation with the use of current chemotherapeutic drugs
is that they lack selective cytotoxicity between cancer cells and healthy cells. Anticancer drugs
are not able to selectively destroy cancerous cells without also harming the normal cells that are
in proximity of the target cells, resulting in damaged organs (13).
To address the important issue of off-target cytotoxicity associated with the use of hydrophobic
anticancer drugs, many different approaches have been developed to improve selectivity of the
drug and to reduce the cytotoxic effects on healthy tissues. The development of novel delivery
systems for these insoluble drugs without the use of organic solvents has received significant
attention (14, 15). Liposomes have been studied as a potential vesicular drug delivery system as
they can encapsulate the drug, and potentially be targeted to tumor cells. However, the physical
degradation, leakage and fusion of liposomes, can lead to untimely drug release (16).
Nanoparticles (NPs) have been used as a vehicle for these insoluble drugs using direct targeting to
tumors, which overcomes the insolubility issue and off-target toxicity (17, 18). However, many
of the different nanoparticle systems result in side effects too; for instance, pulmonary
inflammation and platelet aggregation have been observed (14).
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As a non-particulate alternative, cell penetrating peptides (CPPs), which are short peptides
capable of moving across the plasma membrane (19) may serve as vehicles to transport small
molecule drugs. However, like the drugs themselves, many of the CPPs do not specifically target
tumor cells. While these peptides seem highly effective and nontoxic in vitro, only some are able
to distinguish the target cancer cells from healthy cells in culture due to the loss of anionic lipid
asymmetry attracts the positive charges of the peptide (15). However, in animal models the
specificity is still low and cause toxicity, preventing effective clinical translation (20). Similar to
CPPs, antimicrobial peptides (AMPs) are short cationic peptides that can enter the cell by
disrupting the membrane (21). Certain AMPs also have the ability to translocate cargo across the
cell membrane. Thus, AMPs have been explored and developed as a potential means to deliver
therapeutics to fight infectious diseases but also cancer as anticancer peptides (ACPs) (22). Factors
that slow down the use of ACP in drug development are their low resistance to proteolytic
cleavage, and some ACPs also have low selectivity, thus resulting in high off target toxicity (23).
Additionally, concerns of AMPs’ sequences being close to natural human AMPs have arisen as
they may compromise or trigger natural defense mechanisms (23). As current drugs and their
potential transporters are non-selective, it is imperative to develop a therapeutic strategy that
lowers off-target side-effects by targeting a cancer-specific biomarker.

1.2. Targeted cancer therapy
Targeted therapies are used in the treatment of numerous diseases, including cancer (24-26).
These therapies focus on a molecular target in the diseased cell, a biomarker. For example, tumor
cells are hypermetabolic, produce elevated levels of cell-surface receptors, extracellular growth
factors, and enzymes as they play crucial roles in tumor progression (1, 27). Many therapies, such
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as therapeutic monoclonal antibodies, will target these molecular biomarkers (28); however,
successful targeting of specific proteins is limited by tumor heterogeneity.
Heterogeneity between tumors at different stages of metastasis is caused by genetic instability
(29). Mutational frequencies of genes differ between the many tumor types due to the distinct
signaling pathway specific to each cellular context (30). Intertumor heterogeneity occurs when
there is genetic and phenotypic variation between tumors of different tissues and between different
people (30). Moreover, cancer cells from the same origin might have different genetic variation
(intratumor heterogeneity) (31). This is due to branched tumor evolution (32), wherein a new clone
is unable to outcompete the precursors, resulting in subclonal diversity as the subclones develop
in parallel. The large number of mutations and genetic variations result in merely a subset of
cancerous cells being targeted, while other cells continue to proliferate. Therefore, a successful
anticancer treatment must focus on cellular properties that are common to most tumors and are
intrinsic only to cancer cells, such as tumor-associated acidity.

1.3. Characteristics of cancer cells
Cancerous tissues are characterized by microenvironmental acidosis (33). The extracellular
acidity of cancer tissues is associated with hypoxia and heightened cellular metabolic activity (34).
Tumors have disrupted blood flow due to development of an abnormal vascular network that is
inefficiently organized, resulting in inadequate oxygen delivery (35). This leads to poor perfusion
within the tumor and subsequently low oxygenation. In turn, insufficient oxygenation heightens
tumorous cells glycolytic flux. The high glucose uptake overpowers the ability of the mitochondria
to produce energy, which then the cytosol resorts to glycolysis even in the presence of normal
oxygen levels. This is known as aerobic glycolysis or the Warburg effect (34). Cells will catabolize
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glucose at an increased rate, and this leads to an increased production of anaerobic metabolites,
such as protons (H+) and lactate, which are pumped across the plasma membrane into the
extracellular space (34). The accumulation of these metabolites in the insufficiently perfused
regions results in a decrease in the extracellular pH (35). The release of carbon dioxide from
cancer cells, which is hydrated to form carbonic acid that dissociates into bicarbonate and H+ and
is exacerbated by the overexpression of surface carbonic anhydrases (CAIX and CAXII), also
contribute to the acidic extracellular milieu which supports tumor growth, invasion, aggression,
and development (36).
Another characteristic of cancer cells is that their membranes can contain more anionic lipids
than normal cells at the outer leaflet, leading to an overall negatively charged cell surface. (37,
38). Normal cells primarily have zwitterionic phosphatidylcholine (PC) and sphingomyelin (SM)
on the outer leaflet, while phosphatidylethanolamine (PE) and the negatively charged
phosphatidylserine (PS) are present only in the inner leaflet of healthy cell membranes, resulting
in an overall net neutral charge from the lipids on the outer leaflet (Figure 1) (39). This asymmetric
characteristic is maintained by two ATP-dependent translocases (flippase and floppase). Flippase
actively move the aminophospholipids PS and, to a lesser extent, PE from the outer to the inner
leaflet, while floppase transports PC and SM from the inner to the outer leaflet. (40). If the cell is
damaged and enters apoptosis, the membrane asymmetry is lost due to the inhibition of the
translocases or a change in the intracellular Ca2+ concentration causing activation of a calciumdependent scramblase. Unlike the other two transporters, scramblase is ATP independent and
transports lipids in a non-selective manner (40).
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Figure 1. Characteristics of cancer cells. Representation of two major differences between
normal and cancer cells: (i) distribution of phospholipids between the two cell membranes, and
(ii) the extracellular pH (pHe). Adapted from (41).
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1.4. Peptides as cancer therapeutics
As briefly mentioned before, many different membrane active peptides have been developed
to be used in cancer therapy (15, 21). These types of peptides are divided into three different
groups: antimicrobial, cell penetrating, and tumor targeting peptides (Table 1).

1.4.1 Antimicrobial peptides
The first group consists of peptides that occur naturally or are derived from a protein. These
peptides are cytotoxic as they have membrane binding capacity, can form pores or disrupt
membranes. In addition to being used as a cargo delivery method, these peptides can also be used
as therapeutic molecules. Antimicrobial peptides fall under this first category. AMPs disrupt the
integrity of the cellular membrane, typically through formation of a membrane pore. The pore can
be attained by three different methods: barrel stave, toroidal pore, or as a detergent (22). Many
AMPs can form alpha helix structures. However, these peptides generally tend to be unstructured
in solution at physiological pH. In the presence of lipid bilayer, however, they form an amphipathic
alpha helical structure with their hydrophobic residues aligning one side of the helical axis and the
hydrophilic residues on the other side (42, 43).

As these peptides generally target lipid

membranes, drug resistance is less likely to be developed (44). Cationic AMPs disrupt cell
membranes and induce apoptosis through electrostatic interactions with anionic components of
cancer cell membranes (23). For example, cecropins, isolated from the giant silk moth, have been
shown to induce cell apoptosis and inhibit cell proliferation in cell culture studies (45). Magainins,
derived from the African clawed frog also exhibit similar selective anti-cancer behavior. The
anticancer peptide was toxic to cancer cell, but it did not affect lymphocytes or fibroblast (44).
While AMP/ACPs have shown great potential, the enzymatic degradation and inactivation of
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Table 1. Peptide Sequences
Peptide

Type

Sequence

cecropins

Antimicrobial

KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL2

magainins

Antimicrobial

GIGKFLHSAGKFGKAFVGEIMKS

CADY

Cell penetrating

Ac-GLWRALWRLLRSLWRLLWRA-Cy

pep-1

Cell penetrating

Ac-KETWWETWWTEWSQPKKKRKV-Cy

Tat

Cell penetrating

GRKKRRQRRRPQ

R8

Cell penetrating

RRRRRRRR

Transportan

Cell penetrating

GWTLNSAGYLLGKINLKALAALAKKIL

RGD motif

Tumor targeting

RGD

NGR motif

Tumor targeting

NGR

TMX-1

synthetic

Ac-WNALAAVAAALAAVAAALAAVAAGKSKSKS-NH2

TMX-3

pH responsive

GGWAALAAHAAPALAAALAHAAASRSRSRSR-NH2

LAH4

pH responsive

KKALLALALHHLAHLALHLALALKKA-NH2

MelP5_Δ4

pH responsive

GIGAVLKELADGLPALIDWIEAAQQL

MelP5_Δ6

pH responsive

GIGAVLEELADDLPALIDWIEAAQQL

pHD*

pH responsive

GIGEVLHELADDLPDLQEWIHAAQQL

PSPF*

pH responsive

WSDLAQALSDLAQALSDLAQALSDLAQA

aMel

pH responsive

GIGAVLEVLTTGLPALISWIEEEEQQ-NH2

aRV

pH responsive

RIGVLLAELPELFSLFELMGEEV-NH2

Cyclic pH-Responsive Peptide*

pH responsive

c[WEWEWEWEWC]

GALA

pH responsive

WEAALAEALAEALAEHLAEALAEALEALAA

pHLIP

pH responsive

AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG

ATRAM

pH responsive

GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN

K2-ATRAM

pH responsive

GKAGKAGLLGLEGLLGLPLGLLEGLWLGLELEGN

Y-ATRAM

pH responsive

GYAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN

*One example of a class of peptides.
The cationic amino acids important for membrane interaction are shown in red and the titratable moieties in
blue.
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cationic peptides through interaction with negatively charged serum proteins are impediments to
the clinical use of anticancer peptides.

1.4.2 Cell Penetrating peptides
Unlike AMPs, the principle mode of action of cell penetrating peptides (CPPs), the second
group of therapeutic peptides, is to translocate completely across the cellular membrane and
interact with intracellular targets. Although their exact translocation mechanism is still unknown,
two main methods have been proposed: (1) an energy independent process and (2) an energydependent endocytic process (46). Many CPPs fall under the latter group including penetratin, Tat,
and oligoarginines as they are internalized by an endocytotic pathway, while others including
CADY and pep-1 fall under the former (47, 48). CADY is able to translocate across the plasma
membrane at low temperatures, indicating an energy-independent process. Likewise, pep-1 was
able to translocate beta-galactosidase (β-Gal) across the membrane of lipid vesicles and human
HeLa cells independently of temperature. In fact, the translocation of β-Gal was due to negative
transmembrane potential (48, 49). While energy-independent translocation at the plasma
membrane prevents cargo from being trapped in endosomes, energy-dependent mechanisms may
result in untimely degradation of the biologically active cargo bound to the peptide during
endosomal maturation (46). Hence, efficient endosomal escape is essential for energy-dependent
CPPs.
CPPs can be classified into two other categories: cationic or amphipathic (15, 50, 51). Similarly
to AMPs, cationic CPPs are short arginine- and lysine-rich peptides that rely on their cationic
nature for efficient intracellular accumulation (19).The exemplary Tat peptide is derived from the
transactivator of transcription (TAT) of HIV and discovered as the first CPP. Mutational analysis
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of the Tat protein showed that the highly positively charged N-terminus was necessary for the
entry of the protein into the cell (52, 53). Studies have shown that the Tat peptide can be used to
transport a variety of conjugated cargos across the cell membrane, including anticancer drugs (54,
55). When the anticancer drug Taxol and drug surrogates were conjugated to the cationic CPP
octaarginine (R8), its solubility, biodistribution, cytotoxicity, and phamacokinetics were enhanced.
It was also able to overcome multiple drug resistance (56). Amphipathic CPPs contain both
hydrophobic and hydrophilic regions. The positively charged and hydrophobic residues are
distributed evenly throughout the sequence, resulting in the polar residues aligning one face of the
secondary structure while the nonpolar residues align on the opposite side. Unlike cationic CPPs
which solely rely on ionic interactions for intracellular accumulation, the main interaction of
amphipathic CPPs is the binding of its hydrophobic region with the lipid membrane of the cell if
the peptide has a helical structure in solution (50). If the peptide has a random structure in solution,
it will still rely on its cationic nature to interact with anionic components on the cell surface (50).
TP10, the truncated form of the amphipathic transportan, has shown the ability to transport peptide
nucleic acid into cancer cells (51). However, an important limitation of most CPPs, like Tat, R8,
and transportan, is the absence of tumor cell specificity. This necessitates modifications or fusion
with a tumor-specific ligand for optimal anticancer effectiveness (44).

1.4.3 Tumor Targeting Peptides (TTP)
The third group of cancer therapeutic peptides are those that are specific for molecular markers
on the surface of the cancer cell.

Peptides with arginine/glycine/aspartic acid (RGD) or

asparagine/glycine/arginine (NGR) motifs will bind to integrins overexpressed in tumor
vasculature. Once these peptides bind to the receptor, they can be internalized by the cell through

11

endocytosis. This way they are able to deliver cytotoxic cargo into the cancer cell. The major
drawback of the small RGD peptides as therapeutics is their rapid clearance from the circulation
by the kidneys and the liver (57). Furthermore, as mentioned previously, the disadvantage of
focusing on a specific molecular marker is tumor heterogeneity.

1.4.4 Summarized advantages and disadvantages
Using peptide-based strategies over other drug delivery system has its advantages. Peptides are
stable in physiological conditions, non-immunogenic, and easy to modify and to conjugate many
cargoes, such as protein, nanoparticles, or nucleic acids to deliver into cells. While some of these
peptides mentioned previously were able to inhibit cell proliferation and deliver cargo, many of
these peptides still lack tumor cell specificity either in vitro or in vivo. However, the ones that do
have specificity as they contain a motif to target specific proteins are inadequate due to tumor
heterogeneity. Moreover, these peptides are rapidly degraded by enzymes when injected into
animal models. These are the principle reason why many preclinical and clinical trials based on
the use of peptides, mostly CPPs, have been conducted or are ongoing, but none of them have been
approved as a cancer therapeutic by the US Food and Drug Administration (FDA) (54, 58). There
is a need to find a way for peptides to overcome these limitations. A means to address the
specificity and tumor heterogeneity is to design peptides to target the extracellular pH of tumor
cells.

1.5. pH responsive peptides
Peptides have advantageous properties for application in targeted therapies of acidic diseases.
Peptides that contain glutamate, aspartate, and histidine are appealing molecules to target acidosis
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as they can naturally respond to pH alterations close to the physiology range via titration of the
sidechains. The pKa values of these titratable amino acids (Asp = ~3.5, Glu = ~4.2, His = ~6.6)
will get shifted in different environments (59). Aspartates and glutamates will have a pKa that is
typically higher in hydrophobic environments than in solution, while histidine will observe an
acidic shift (59-63). In acidic environs, aspartate and glutamate side chains get protonated, which
increases the overall hydrophobicity of the peptide, which results in an increased affinity for the
nonpolar region of the cell membrane. On the other hand, the imidazole sidechain of histidine is
hydrophobic in its deprotonated state, while it is hydrophilic and positively charged in its
protonated state. This results in favorable interactions between the peptide and the nonpolar
regions of the membrane at physiological pH (64). Additionally, therapeutic molecules can be
attached to the peptides and, thus, be transported across the cellular plasma membrane (Table 1).

1.5.1 TMX
Several different peptides have been designed to have pH-sensitive properties. A synthetic
peptide, TMX-1, was developed and studied by White and colleagues and shown to be able to
spontaneously insert across lipid bilayers (60, 65). However, TMX-1 was considered nontranslatable as the peptide strongly aggregated in solution. In the presence of lipids, it also showed
conformational heterogeneity of both water-soluble and membrane-bound forms (65). The issue
of aggregation was addressed when the peptide was redesigned by including an alanine heptad
repeat, which results in the formation of alanine coils, and a central proline. Furthermore, a pair
of histidines were added to allow pH-dependent changes in peptide topology.

While the

redesigned peptide, TMX-3, is resistant to aggregation, the peptide was unable to adopt a
transmembrane (TM) configuration. It had been proposed that substituting some of the alanines
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for leucines would result in a hydrophobic state that would result in a peptide that would
energetically prefer the transmembrane conformation (60).

1.5.2 LAH4
The synthetic amphipathic LAH4 peptide shows both antimicrobial and cell penetrating
activity while being designed to be pH sensitive (61). Its higher affinity towards anionic lipids is
similar to AMPs, and it allows for more specific targeting of membranes with exposed PS (66).
Similar to CPPs, the polar and nonpolar residues align at opposite sides of the alpha helix. LAH4
consists mainly of leucines and alanines with lysines at both termini for solubility. Furthermore,
the addition of lysines allows for electrostatic interactions with DNA and results in high affinity
for anionic lipids. The pH-sensitivity of the peptide arises from the presence of four histidines (67).
At neutral pH, the peptide is in its transmembrane state, while the peptide remains on the surface
of the lipid membrane at pH < 6. With this pH-triggered mechanism, LAH4 is able to deliver DNA
to cells through endosomal uptake. As the interior of the endosome acidifies (pH 5.5), the peptide
that was in its TM state at physiological pH will undergo a conformation change and adopt an inplane orientation. This in-plane orientation allows for antimicrobial activity and disrupt the
endosomal membrane and deliver the DNA to the cytosol (66).

1.5.3 pHD Peptides
Hristova, Wimley, and colleagues have also attempted to design a pH-sensitive peptide based
on the analog of the bee venom lytic peptide melittin, MelP5, (68). MelP5 forms pores that, unlike
melittin itself, are large and can last for hours. This allows for formation of a channel that
macromolecules can use to cross the membrane bilayer. MelP5 was redesigned to control the pore
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formation of the peptide by pH (MelP5_Δ4 and MelP5_Δ6). Four to six residues have been
mutated to aspartate or glutamate so that the peptide has pH-responsive properties. The goal was
to deliver macromolecules into the cytoplasm through endocytosis. Endosomal acidification
should trigger the peptide to form pores and release the macromolecules into the cell. While the
pH-sensitive properties were obtained, the mutated analog lost the ability of the parent peptide,
MelP5, to form macromolecule-sized pores in membranes. With the knowledge they gained with
the design on MelP5, Hristova, Wimley, and colleagues developed a rational combinatorial peptide
library. Their goal was to identify sequences that do not permeabilize the membrane at high pH
and concentration but form macromolecule-sized pores in membranes at pH 5 and low peptide
concentration. This peptide family is also known as the pH-dependent delivery (pHD) peptides
(69). Out of the ten peptides from that library that successfully have the desired properties, the
ones with five acidic residues were more effective and have a higher apparent pKa than the ones
with six acidic residues. The helical spacing on the helix combined with the conserved glutamine
residue and the preference of glutamate over aspartate suggest that sequence-specific interactions
affect the pH-triggered activity of the peptides.

1.5.4 pH-Switchable Pore Formation Peptides
The pH-switchable pore formation (PSPF) peptides are designed with the premise to form
pores inside membranes at pH 5.5, which is the pH of the endosomal environment (70). Degrado
and colleagues were trying to mimic biological AMPs while overcoming their limitations. PSPFs
are disordered and nonspecifically bind to the membrane surface at physiological pH, and they are
inserted and self-associated to the membrane to form pores at acidic pH. Unlike some AMPs that
disrupt the membrane by a detergent-like mechanism, the mechanism of PSPF would result in
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minimal membrane perturbations, and the integrity of the endosome would be maintained. This
was shown by the release of ATP and miRNA, but not hemoglobin, from red blood cells,
suggesting a lack of membrane rupture. Furthermore, their concept for a pore-driven mechanism
is that lower amounts of peptide are needed compared to a nonselective detergent mechanism that
necessitates higher peptide density across the entire membrane surface. To enhance their peptide
design, Degrado and colleagues are considering ways to increase the peptide population of inserted
state versus the surface-bound state.

1.5.5 AMP Derived pH-Responsive Peptide
AMPs have previously been used to enhance polyethylenimine (PEI)‐mediated gene
transfection by increasing endosomal release (71). To improve the transfection efficiency, Zhang
and colleagues replaced the positively charged residues on melittin and RV-23, a peptide derived
from Rana draytoni, analogs with glutamates (72). These new peptides (aMel and aRV) resulted
in pH‐sensitive lytic activity as the hemolytic activity of both peptides was higher at low pH versus
physiological pH. The designed peptides interacted with the PEI/DNA complex and were able to
enhance the PEI‐mediated transfection efficiency as they experienced increased endosomolytic
activity. Moreover, they were able to keep low cytotoxicity.

1.5.6 Cyclic pH-Responsive Peptide
To combat rapid peptide enzymatic degradation, Weerakkody and colleagues have designed
pH-sensitive negatively charged cyclic peptides (73). Cyclic peptides have shown enhanced
enzymatic stability compared to linear peptides (74). These novel cyclic peptides demonstrate pHsensitive interaction with membranes of liposomes, cultured HeLa cells, and tumors in mice
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model. As approximately 0.7 kcal/mol of free energy is released at low pH., it is predicted that the
peptides would be able to translocate cell-impermeable cargo across membrane and target acidic
tumors.

1.5.7 GALA
A well-established synthetic, fusogenic peptide with pH-sensitive membrane-insertion
properties is the GALA peptide (75, 76). GALA, named for the residues that make up the majority
of the peptide (glutamate, alanine, and leucine), goes through a random coil-to-α-helical transition
when pH is decreased from physiological to acid pH. At acid pH, GALA will insert into lipid
membranes it as it adopts an amphipathic helical structure due to the protonation of the glutamic
acid residues. In its helical state, GALA irreversibly aggregates and is inserted into the membrane
(77, 78). Furthermore, the peptide is known to self-associate in solution at concentrations higher
than 16 μM (79). Aggregation is a characteristic of cytolytic behavior in peptides. Indeed, GALA
at low pH has comparable levels of lytic activity as melittin. However, GALA lacks the positively
charged amino acids that are proposed to be necessary for the lytic activity of melittin (76). As
the peptide was designed with viral fusion protein in mind, GALA does promote membrane fusion
of small unilamellar vesicles at low pH. Unlike other fusogenic peptides that are only involved in
vesicle aggregation, such as synexin and polylysine, GALA is involved in both vesicle aggregation
and the actual fusion steps (80).

1.5.8 pH-Low Insertion Peptides
Another well-developed pH-responsive membrane peptide is the pH-low insertion peptide
(pHLIP), which is derived from the C-helix of bacteriorhodopsin (81). In alkaline conditions, the
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peptide associates with the lipid membrane (peripheral state), while a decrease in pH leads to the
insertion of pHLIP into the membrane as an alpha helix (transmembrane state; Figure 2) (82, 83).
While many of the other pH-responsive peptides were designed to behave similarly to AMPs and
CPPs, pHLIP does not disrupt the integrity of the cell membrane when its inserted unlike GALA
and the pHD peptides (84, 85). Furthermore, pHLIP is able to selectively deliver several different
molecules, such as toxins, nucleic acids, and fluorescence imaging markers, into tumor cells in
vitro and in vivo (85, 86). Although cell penetrating peptides and pHLIP both deliver cargo across
the cell membrane, they differ in the fact that CPPs need to be completely internalized to deliver
their cargo, while pHLIP does not. More importantly, pHLIP has been shown to target tumors in
vivo (87-89).
The pH-low insertion peptide has several limitations. Its insertion pK, which is the pH at which
50% of the peptides are inserted into the membrane, is pH 5.7 in palmitoyloleoylphosphocholine
(POPC) liposomes (90). As the extracellular pH of tumors ranges from 6.4 to 7.0 (91), pHLIP
does not localize to the tumor optimally. Moreover, the insertion pK decreases significantly in
lipid membranes that include phosphatidylserine (PS) (90, 92). The insertion pK decreased and
saturates at approximately 5.3±0.1 at 5% PS (90). This is rather too acidic for clinical applications
as the extracellular pH of tumors is more than one whole pH unit higher than 5.3 (33). For optimal
cancer cell retention, it would be ideal for the peptide insertion pK to fall within the range of the
extracellular pH of tumors.

Furthermore, pHLIP has a propensity to aggregate at low

concentrations (>7 µM). While pHLIP seems successful in laboratory studies, these limitations
can slow down its transition to clinic trials.
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Figure 2. Representation of the three different states of pHLIP. Adapted from (93).

19

1.6. Serum albumin as a carrier in the bloodstream
As mentioned previously, the major impediment for using peptides as therapeutics is their
rapid clearance from the circulation due to renal filtration and low metabolic stability. For instance,
insulin, a proteolytically stable peptide, has a half-life of 4 to 6 minutes once it gets into the
bloodstream (94). The prevalent approach to avoid this fast clearance is to attach the therapeutic
molecule to a ligand that binds to serum proteins with long half-lives. As serum albumin is
responsible for the majority of small molecule binding in plasma, it is the commonly chosen carrier
molecule in therapeutics (95). Due in part to its size being larger than the renal filtration threshold,
human serum albumin (HSA) has the high plasma half-life of 19 days (96). It also is the most
abundant protein in plasma as it accounts for about 50%-60% of plasma proteins. Insulin detemir,
insulin degludec, and liraglutide are peptides that are currently used in as therapeutics (97-99). All
three peptides have been conjugated to a fatty acid chain, such as myristic and palmitic acid, that
will bind to albumin. All three peptide-albumin complexes resulted in a longer life-time in
circulation due to reduced filtration by the kidney compared to the nonlipidated peptide version.

1.7. Summary of conducted work
We designed the acidity-triggered rational membrane (ATRAM) peptide to have pHresponsive properties so that it can have the duality of being a surface-bound or transmembrane
peptide (Table 1). Using biophysical techniques, we have determined that ATRAM is a highly
soluble peptide that adsorbs onto the lipid membrane surface at physiology and basic pH and will
fold into the membrane as a transmembrane α-helix at acidic conditions. Its pH-triggered property
arises from the addition of four glutamates in its sequence. Furthermore, our designed peptide can
maintain its pH-responsiveness in cultured cancer cells.
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With additional biophysical experiments and fluorescence microscopy, we gained insight
to the mechanism of ATRAM’s insertion into liposomes. We determined its membrane topology
by assessing the cellular uptake of fluorescently labeled ATRAM coupled to PEGylated liposomes.
The results confirmed that ATRAM inserted unidirectionally with its C-terminus across the plasma
membrane. Kinetic studies indicated that the peptide undergoes several intermediate steps before
it is fully inserted into the membrane. In addition, leakage and binding studies gave us insight into
oligomerization and binding cooperativity.

The peptide exhibits an extended bloodstream

circulation in mice. We hypothesize that ATRAM uses human serum albumin in the blood to
circumvent enzymatic degradation as we have shown that the peptide binds to lipid membranes
after pre-incubation with the protein in biophysical methods.
Compared to healthy cells, cancerous cells have the negatively charged phospholipid,
phosphatidylserine, exposed on the outer leaflet of their plasma membranes. With biophysical
techniques, we determined that the acidity-targeting properties of ATRAM do not change in
liposomes with increasing concentrations of the negatively charged lipid, but some membrane
related properties did. Also, by modifying the sequence of ATRAM at the N-terminus, the
properties of the peptides were altered, particularly the pK of insertion. The changes in the
peptides’ properties are the most significant with the addition of phosphatidylserine.
My work highlights the potential of ATRAM to be developed as a specific therapeutic
agent for diseases that lead to acidic tissues, including cancer. Understanding how ATRAM
interacts with the lipid membrane and is able to avoid immediate degradation and renal clearance
in vivo can broaden the design and application range of peptides as therapeutics. By rationally finetuning the sequence of ATRAM, we propose we can increase its efficacy to insert into cancer cell
membranes.
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Chapter II. A novel soluble peptide with pH-responsive membrane
insertion
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A version of this chapter was originally published by Vanessa P. Nguyen, Daiane S.
Alves, Haden L. Scott, Forrest L. Davis, and Francisco N. Barrera in Biochemistry 2015, 54,
6567−6575 (100).
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2.1. Abstract
Several diseases, such as cancer, are characterized by acidification of the extracellular
environment. Acidosis can be employed as a target to specifically direct therapies to the diseased
tissue. We have used first principles to design an acidity-triggered rational membrane (ATRAM)
peptide with high solubility in solution that is able to interact with lipid membranes in a pHdependent fashion. Biophysical studies show that the ATRAM peptide binds to the surface of lipid
membranes at pH 8.0. However, acidification leads to the peptide inserting into the lipid bilayer
as a transmembrane α-helix. The insertion of ATRAM into membranes occurs at a moderately
acidic pH (with a pK of 6.5), similar to the extracellular pH found in solid tumors. Studies with
human cell lines showed a highly efficient pH-dependent membrane targeting, without causing
toxicity. Here we show that it is possible to rationally design a soluble peptide that selectively
targets cell membranes in acidic environments.
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2.2. Introduction
Targeted therapies hold great promise for the treatment of numerous diseases. This class of
therapies often relies on the expression of a molecular target in the diseased cell. However, drug
resistance frequently results from mutation, downregulation, or signaling cross-talk of the
molecular target (101). The successful targeted therapies of the future will benefit by being
directed instead at a prevalent feature of the disease. Several pathological states, such as cancer
(102), ischemia, and inflammation, have a significantly disrupted pH balance resulting in acidosis.
In the case of cancer, alterations in the metabolism and physiology of solid tumors cause
extracellular acidosis (34, 103). Strikingly, it has been recently shown that acidosis favors tumor
aggressiveness. In particular, acidity enhances metastasis (104) and local invasion (35) and plays
an immunosuppressive role (105). Therefore, technologies that target therapeutic cargos to acidic
tissues might be of general use for fighting acidic diseases such as cancer. Furthermore, as a
consequence of the competitive advantage acidosis confers to cancer cells, therapies targeting
acidosis might be less susceptible to resistance.
Peptides are attractive molecules for the delivery of cargo to acidic diseased tissues. Peptides
show high efficacy, selectivity, and safety (106) and are also naturally endowed to respond to
acidification, by means of the titration of the acidic residues aspartate and glutamate. Here, we
report the rational design of an acidity-triggered rational membrane (ATRAM) peptide, which
responds to acidification by inserting into the membrane of tumor cells.

2.3. Experimental Procedures
Liposome Preparation. Stocks of POPC (1-palmitoyl-2- oleoyl-sn-glycero-3-phosphocholine)
(Avanti Polar Lipids, Inc.) were prepared in chloroform. Appropriate aliquots of lipids were dried
first with argon gas and then under a vacuum overnight. The dried lipid films were rehydrated
25

using 10 mM NaPi buffer (pH 8.0). Large unilamellar vesicles (LUVs) were prepared with a MiniExtruder (Avanti Polar Lipids, Inc.) through a 100 nm pore size membrane (Whatman).
Peptide Preparation and Conjugation. Peptides were prepared by FMOC solid phase synthesis
and purified by reverse phase high-performance liquid chromatography to >95% purity. For
biophysical experiments, the ATRAM peptide was labeled at the N-terminus with NBD
(nitrobenzoxadiazole) using NBD-X succimidyl ester or rhodamine (5,6-carboxytetramethylrhodamine, succinimidyl ester, Anaspec). For microscopy, ATRAM and pHLIP were labeled at
the N-terminus with BODIPY FL-X, which contains a seven-atom spacer between the dye and the
conjugation point. Free dyes were removed by gel filtration through a PD-10 column, and matrixassisted laser desorption ionization time of flight was employed to determine that a single dye
molecule was bound per peptide molecule. The expected and observed molecular mass (M + H+)
values were 3623.1 and 3624.0, respectively.
NBD Lipid Binding Assay. The assay was performed as described elsewhere.9 Briefly,
lyophilized samples of ATRAMNBD were rehydrated in 10 mM NaPi (pH 8) at a final
concentration of 1 μM and incubated with increasing concentrations of POPC LUVs. Emission
spectra were recorded on a Photon Technology International Quanta Master fluorometer. The
appropriate lipid background was subtracted in all cases. Data were analyzed by following the
fluorescence intensity change at 540 nm. Data were fitted with OriginLab using eq 1:

Fo + ∆F ×

Kp × x

55.3+Kp × x

(1),

where Fo is the initial fluorescence intensity, Fmax is the maximal fluorescence intensity, x is the
lipid concentration, and 55.3 is the molar concentration of water. Equation 1 was used to determine
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the partition coefficient, Kp, defined as the ratio of concentrations of a compound in a mixture of
two phases.
Intrinsic Fluorescence Spectroscopy. For the pH titration experiments, 1 μM ATRAM was
incubated for at least 1 h with POPC LUVs to reach a 1:200 molar ratio. The pH of the samples
was changed accordingly with 100 mM buffers (sodium acetate, MES, or HEPES). Tryptophan
fluorescence emission spectra were recorded at an excitation wavelength of 280 nm.
Measurements were performed on a Photon Technology International Quanta Master fluorometer.
The appropriate lipid background was subtracted. The data were analyzed by monitoring the
spectral maxima, which were then fitted to determine the pK, using eq 2:
𝐹𝐹𝑎𝑎 +𝐹𝐹𝑏𝑏 ×10𝑚𝑚(𝑝𝑝𝑝𝑝−𝑝𝑝𝑝𝑝)
1+10𝑚𝑚(𝑝𝑝𝑝𝑝−𝑝𝑝𝑝𝑝)

(2),

where Fa is the acidic baseline, Fb is the basic baseline, m is the slope of the transition, and pK is
the midpoint of the curve.
Circular Dichroism. Measurements were performed on a Jasco J-815 spectropolarimeter at 25
°C. Peptide was incubated with lipid in 10 mM NaPi (pH 8.0) or 10 mM sodium acetate (pH 4.1).
Samples were prepared as described above. The lipid:peptide ratio was 100:1 with a final peptide
concentration of 5 μM. The appropriate lipid backgrounds were subtracted.
Oriented Circular Dichroism. OCD was performed as described elsewhere (90). Briefly, the
Langmuir−Blodgett method was used to form a monolayer on a demountable quartz cuvette with
a KSV NIMA trough. A peptide/lipid solution (1:50 molar ratio) at pH 4 or 8 was incubated with
the monolayer under 100% humidity to complete vesicle fusion to obtain supported bilayers. The
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OCD spectrum was measured on a Jasco J-815 spectropolarimeter, and appropriate backgrounds
were subtracted.
Calcein Leakage Assay. A dried POPC lipid film was rehydrated with 50 mM calcein in 10 mM
HEPES and 50 mM EDTA (pH 8). Large unilamellar vesicles were prepared as described above.
Free calcein was removed by gel filtration through a PD-10 column. Peptide was added to the
calcein/ LUV suspensions at different concentrations to achieve final peptide:lipid molar ratios of
0.0025−0.5%. After incubation at room temperature for 30 min, calcein leakage was tracked by
measuring fluorescence using a Synergy 2 microplate reader (BioTek) at an excitation wavelength
of 485 nm and an emission wavelength of 528 nm. Complete calcein release was reached by adding
20% Triton X-100.
FRET Oligomerization Assay. Lyophilized samples of ATRAM, ATRAM-NBD (donor), and
ATRAM-Rho (acceptor) were rehydrated in 10 mM NaPi buffer (pH 8). The donor was held at
0.1 μM, and the acceptor was used in a range of concentrations from 0 to 0.5 μM. Unlabeled
peptide was added to keep the final peptide concentration constant at 2 μM. To minimize
scattering, polarizers were employed: excitation polarizers set to 90° and emission polarizers set
to 0° (107, 108). Lipid blanks were subtracted in all cases. The final lipid:peptide ratio was 200:1.
Vesicle Fusion Assay. FRET was used to determine the amount of vesicle fusion induced by
ATRAM. PE-Rho and PENBD were from Avanti Polar Lipids. Vesicles containing 99 mol %
POPC, 0.5 mol % PE-NBD (donor), and 0.5% PE-Rho (acceptor) were prepared like POPC
vesicles. The final ATRAM concentration was 1.9 μM. Unlabeled POPC vesicles were added to
vesicles containing labeled lipids in the presence of ATRAM. POPC vesicles containing labeled
lipids were measured separately to determine the maximal amount of energy transfer. Triton X-
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100 (final concentration of 0.7%) was added to samples containing POPC vesicles with labeled
lipids to inhibit the FRET signal to determine the smallest amount of energy transfer. Appropriate
lipid blanks were subtracted from each sample to correct for the effect of light scattering caused
by lipids. POPC vesicles containing 0.5 mol % PE-Rho in the absence and presence of Triton X100 were used to determine the correction factor to account for the disturbance in the emission
spectra caused by the addition of Triton X-100. The percent fusion was calculated using eq 3:
(sample−control)
(𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇−𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐)

× 100 (3),

where Sample contains ATRAM, labeled vesicles, and unlabeled vesicles; Control is identical but
without ATRAM; and Triton is POPC containing labeled lipids after the addition of Triton X-100.
All intensity values were measured at 594 nm.
Cell Binding Assays: Plate Reader and Confocal Microscopy. A375 and H358 cells (ATCC)
were washed twice with phosphate-buffered saline supplemented with 1 mM MgCl2 and 100 μM
CaCl2 (PBS++) and incubated with 2 μM peptide (ATRAM-BODIPY or pHLIP-BODIPY) for 5
min, followed by an incubation of 90 s with PBS++ containing 10 mM dextrose (Sigma-Aldrich)
at different pHs (5, 6, and 7). Cells were then washed once in the same buffer and subsequently
fixed with 4% paraformaldehyde for 30 min. Plate reader binding assays were performed using
cells cultured in a 96 black collagen-coated plate (Corning), and the fluorescence intensity was
detected at 488 nm in a plate reader (Synergy 2, Biotek). The quantification analysis is a result of
three independent experiments performed in triplicate. Cell imaging was performed at room
temperature using an inverted Olympus Ix83 microscope with a confocal laser scanning
VTHAWK system equipped with a 60 × 1.35NA objective from Visitech International, running
metamorph, and a Hamamatsu EM-CCD camera (model C9100-13). Contrast and brightness
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settings were chosen so that all pixels were in the linear range. Images from different channels
were overlaid using ImageJ.
Cell Proliferation Assay (MTS). Cell viability was measured using the CellTiter 96 Aqueous One
Solution. Briefly, cells were seeded (104 cells/well) 2 days prior the experiments on a 96-well
plate, exposed to vehicle (CT) or ATRAM at different concentrations (0.5, 1, and 2 μM), and
incubated for 24 h. The results are representative of three independent experiments, performed in
quadruplicate. The inhibition of cell proliferation was expressed as the percentage of vehicle
control.

2.4. Results
The potential of peptides for targeting acidosis is exemplified by the pH-low insertion peptide
(pHLIP). The pHLIP, developed in the laboratories of Engelman, Reshetnyak, and Andreev, is a
soluble peptide that binds to membranes in a mostly unstructured conformation at neutral pH.
Upon acidification, the pHLIP undergoes a conformational change, forming a transmembrane
(TM) α-helix as it spans the membrane (81, 109, 110). Several residues important for pHLIP
properties, such as the acidic groups responsible for the pH dependency, and a central proline
residue that increases solubility (111), were included in the sequence of the ATRAM peptide
(Figure 3A). Glutamates were chosen over aspartates, because they have higher pKa values, more
appropriate for the targeting of acidic diseased tissues. For the rest of the ATRAM sequence,
residues were selected to yield an overall hydrophobicity similar to that of pHLIP (112) by
balancing the more hydrophobic leucine with the less hydrophobic alanine and glycine (Gly). Gly
was preferred over alanine because, interestingly, the conformational propensity of Gly is strongly
dependent on the environment. Hence, while in solution Gly destabilizes the secondary structure
found in aggregates, in membranes Gly favors the formation of helices (113, 114). Hence, we
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believe that Gly minimizes aggregation in solution without disrupting α-helix formation in
membranes. Finally, a single tryptophan residue was introduced into the ATRAM peptide to
perform intrinsic fluorescence evaluation of the properties of the peptide.
We found that ATRAM readily dissolved in aqueous buffer (see details below), allowing us to
evaluate the interaction with lipids. We first studied the binding of the ATRAM peptide to
synthetic vesicles. As a lipid of choice, we selected POPC, because its phosphatidylcholine
headgroup is the most abundant in the eukaryotic plasma membrane (115, 116), while also
containing saturated and unsaturated fatty acids. To accurately measure the binding of ATRAM to
POPC LUVs, we labeled the peptide with an environmentally sensitive fluorescent probe, NBD
(90). We observed that incubation with POPC at pH 8.0 caused a large increase in the fluorescence
of the NBD conjugated to ATRAM (Figure 3B, blue symbols), as well as a blue-shift in the spectral
maximum (Figure 3B, inset). Both spectral changes are characteristic of dehydration of the NBD
group (117-119), suggesting that ATRAM binds to lipid membranes. We next studied whether the
interaction of ATRAM with membranes was pH-responsive, as required for the targeting of
diseased cells in acidic environments. For this purpose, we monitored the intrinsic fluorescence of
the single tryptophan residue (Figure 3A, underlined). A pH titration experiment was performed
for samples of ATRAM incubated with POPC. Upon acidification, we observed a blue-shift in the
emission spectrum from ∼340 to ∼330 nm and a large increase in fluorescence (Figure 3C). From
the obtained spectral maximum curve, we determined the membrane insertion pK, defined as the

midpoint of the sigmoid, with a value of 6.51 ± 0.09. The blue-shift of the intrinsic fluorescence
of ATRAM indicated that at acidic pH values the tryptophan in the peptide was more deeply buried
in the membrane than at neutral pH, suggesting a tighter interaction. To evaluate how membrane
affinity could depend on pH, we repeated the NBD lipid binding experiments at pH 6.0 (Figure
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3B, red symbols). We observed that ATRAM bound more readily to POPC at pH 6.0 than at pH
8.0. We analyzed the binding isotherms to determine the partition coefficient, Kp, with values of
(5.5 ± 2.5) × 105 at pH 8.0 and (16.5 ± 2.5) × 105 at pH 6.0, demonstrating that ATRAM binds to
membranes with higher affinity under acidic conditions.
To study the conformation of ATRAM in the membrane, we employed circular dichroism (CD)
spectroscopy (Figure 3D). At pH 8 (blue line), the CD spectrum showed a minimum of 204 nm
and a small shoulder at 222 nm. These spectral features are typically observed for partially
disordered peptides with some helical content (120). Interestingly, at acidic pH (red line), the
helical content increased, as shown by the large decrease in the magnitude of the signal at 222 nm,
the shift of the minimum from 204 to 208 nm, and the large increase in ellipticity at 195 nm. We
performed a rough quantification of the helical content at both pH values. By considering for 100%
α-helix a [Θ] of −36000 deg cm2 dmol−1 residue−1 (121), we estimated that the helical content
increased from ∼12% at pH 8 to ∼37% at pH 4. However, the membrane alignment of the helical
region of ATRAM was not known. To gain information about the helical orientation with respect

to the plane of the bilayer, we prepared supported bilayers and performed oriented CD (OCD)
experiments (122, 123). When α-helices span the membrane, the OCD spectrum characteristically
displays a broad minimum at ∼220−225 nm and a shoulder with positive ellipticity at 190−195
nm. These characteristics were observed at acidic pH (Figure 3D, inset), indicating that ATRAM

adopts a TM orientation at low pH. On the other hand, the OCD spectrum of an α-helix lying
parallel to the plane of the membrane shows a much more intense negative signal and more clearly
resolved minima at ∼205 and ∼222 nm, which are similar to our data at pH 8. The OCD data thus

indicate that ATRAM lies parallel to the membrane plane at neutral pH, but it responds to
acidification by inserting as a TM α-helix.
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Figure 3. Biophysical characterization of the ATRAM peptide. (A) Sequence of ATRAM. The
acidic moieties, glutamic acid and free C-terminus, are shown in bold; proline is shown in italics,
and the single tryptophan introduced for intrinsic fluorescence experiments is underlined. The
sequence of pHLIP is shown for comparison. (B) POPC binding assay of ATRAM-NBD (1 μM)
at pH 8.0 (blue symbols) and pH 6.0 (red symbols). The fluorescence intensities were normalized
to the maximal value. Curves were fitted to eq 1 (black lines). The inset shows the NBD
fluorescence spectra at 10 and 400 μM POPC (solid and dashed lines, respectively) at pH 8. (C)
Representative pH titration curve obtained by monitoring the tryptophan fluorescence spectral
maximum of ATRAM in POPC (n = 4). The line is the fitting to eq 2, to determine the pK and the
slope of the titration. The slope obtained for ATRAM (1.6 ± 0.4) was similar to the value for the
pHLIP in the same lipid (1.2 ± 0.3) (92). The inset shows the tryptophan fluorescence spectra of
ATRAM in POPC LUVs at pH 4.3 (red line) and pH 7.7 (blue line). (D) Circular dichroism spectra
of ATRAM in POPC at different pH values. Data shown for the ATRAM peptide with POPC
vesicles at pH 7.9 and 4.1 (blue and red lines, respectively). The inset shows the OCD spectra in
POPC at pH 4.1 (red line) and pH 8.0 (blue line).
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Toxicity to Healthy Cells Poses a Significant Concern in the Design of Membrane Active
Peptides. Numerous examples of peptides that disrupt membranes by formation of pores or
membrane solubilization or fusion exist (55, 77, 124-126). To rule out the possibility that ATRAM
might disrupt the integrity of cell membranes, we performed different assays on lipid vesicles and
cells. We studied first whether ATRAM induced vesicle fusion or hemifusion by performing a
FRET assay with two different fluorescently labeled lipids. Figure 4A shows that ATRAM induced
no statistically significant fusion or hemifusion of POPC LUVs, neither at pH 8.0 nor at pH 4.0.
We also performed an assay to study vesicle leakage of encapsulated calcein. A previous report
showed that pHLIP caused only minor calcein release, in agreement with data indicating that
membrane integrity is not significantly disrupted by pHLIP (84). We performed a similar assay
comparing pHLIP and ATRAM (Figure 4B). We observed that the signal was similar for both
peptides at most peptide:lipid ratios, and only slightly higher for ATRAM at the highest
concentration. Intrigued by the leakage results in synthetic vesicles, we performed an assay to
study whether ATRAM disrupted the membrane of cells. We performed a cell viability assay in
two different cell lines (Figure 4C) that shows that ATRAM does not cause cell toxicity. This
result indicates that ATRAM did not disrupt cellular membranes at any of the concentrations
assayed.
To study whether the ATRAM peptide was capable of self-assembly, we performed
oligomerization assays in solution and in the membrane-inserted state at pH 4. Protein
oligomerization is typically associated with a folded state, because protein− protein interfaces tend
to adopt a well-defined conformation. We first employed CD to determine the structure adopted
by the ATRAM peptide in solution. The CD spectrum at 5 μM displays a minimum at ∼200 nm,
indicating that the peptide is largely unstructured. However, a small shoulder at 222 nm suggests
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Figure 4. Membrane interaction of the ATRAM peptide. (A) FRET vesicle fusion assay. The
effect of ATRAM on vesicle fusion/hemifusion was determined at pH 4.0 (TM state, left) and pH
8.0 (interfacial state pH, right). The curves show data from vesicles in the absence of peptide
(dashed red line), in the presence of peptide (blue line), and membrane disruption by Triton X-100
(green line). (B) Comparison of the effect of ATRAM and pHLIP on membrane leakage. The
fluorescence intensity of calcein encapsulated in POPC vesicles was monitored after the addition
of peptide (0.0025−0.5 mol %) in 10 mM NaPi (pH 8.0): (○) ATRAM and (●) pHLIP (n = 3). (C)
MTS cell viability assay performed in the presence of ATRAM for two different human cell lines:
A358 (black) and H358 (gray). Data show the cell viability at increasing ATRAM concentrations
compared to that of nontreated control cells (CT). Results are the means of three independent
experiments. No statistically significant cell toxicity was observed at any of the ATRAM
concentrations. (D) Solubility studies of ATRAM in a 10 mM NaPi solution (pH 7.9) at increasing
concentrations. CD spectra are shown for 5 and 200 μM peptide (solid and dashed lines,
respectively). The inset shows the fluorescence spectral maxima of ATRAM at increasing
concentrations.
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minor helical structure (Figure 4D). Increasing the peptide concentration to 200 μM caused only
small CD changes, which suggest a minor increase in helicity from ∼5 to ∼10%.25 We obtained

further insights by monitoring the intrinsic fluorescence of ATRAM at increasing concentrations

(Figure 4D, inset). At all concentrations, the sole tryptophan in the peptide was highly solvated, as
indicated by the spectral maximum between 350 and 352 nm. Nonetheless, a small, seemingly
nonlinear shift was observed, compatible with the presence of some concentration-dependent
peptide self-association in solution. However, because the peptide at 200 μM is largely unfolded,
and the tryptophan is highly hydrated, we favor the possibility that the monomer is the main species
present even at high concentrations. Finally, we performed a FRET experiment to characterize
whether ATRAM self-associated in the TM form (Figure 5). We observed FRET efficiency values
higher than those expected for a monomer (○), suggesting that ATRAM is in an oligomeric state.
Figure 5 shows data obtained under similar conditions for helix α5 of Cry1Ac (△), postulated to
form a transmembrane tetramer (127, 128). The FRET of ATRAM was significantly lower,
suggesting that the ATRAM peptide assembles into a small oligomeric species, a dimer or a trimer.
Our data showed that ATRAM interacted in a pH-dependent fashion with synthetic vesicles.
However, it was critical to establish whether the desirable properties of the peptide were
maintained in cells. The ability of ATRAM to bind to cultured cells was studied first by
fluorescence microscopy for two different human cancer cell lines, A375 (malignant melanoma)
and H358 (bronchioalveolar carcinoma) (Figure 6A). To explore whether ATRAM showed
potential for targeting acidosis, experiments at decreasing pH values were performed in parallel
with the well-established pHLIP (86, 109, 110, 129). We labeled both peptides with a fluorescent
dye, BODIPY FL-X, to monitor their cellular distribution. After a brief incubation with the
peptides, cells were rinsed with solutions of different pH values, and the fluorescent signal was
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A

B

Figure 5. Self-assembly of the ATRAM peptide. The oligomerization of the TM state of
ATRAM was studied using FRET. Panel A shows the fluorescence spectra. Increasing amounts of
ATRAM-Rho (acceptor) were added to the samples, and the intensity of the FRET signal increased
through quenching of ATRAM-NBD (donor), which was kept at a constant concentration (n = 3).
Panel B shows the calculated FRET efficiency values for ATRAM (●). The line shows the
theoretical FRET efficiency values expected for random encounters of a TM monomeric peptide
(○) (82, 130). To guide the discussion, we show FRET data for oligomeric helix α5 of Cry1Ac of
Bacillus thuringiensis (△) (128).
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Figure 6. pH-dependent interaction of ATRAM with cells. (A) Confocal images of ATRAMBODIPY and pHLIP-BODIPY in two cell lines: A375 (top row) and H358 (bottom row). Images
compare the pH-dependent targeting of cells by ATAM and pHLIP. The gain employed was
identical in all panels and selected to avoid saturation of the ATRAM pH 5 samples. Typical results
from one of three experiments are presented. The bar is 20 μm. (B) Plate reader quantification at
pH 5.0 (black), pH 6.0 (gray), and pH 7.0 (white). Data were normalized to the maximal
fluorescence detected in each experiment. Results are means of three independent experiments,
and the error bars show the standard deviation. Student’s t test: NS, nonsignificant; *p < 0.05; and
**p < 0.01.
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evaluated. Interestingly, ATRAM was able to bind to cells in a pH-dependent fashion, with
stronger cell interaction at acidic pH values. To quantify the association with cells, the total
fluorescence signal for the bound peptides was measured in a plate reader assay. Figure 6B depicts
the quantification of the pH-dependent interaction with the two cell lines. The results indicated
that the overall level of binding of ATRAM to both cell lines was higher than for pHLIP.
Furthermore, it was evident that ATRAM targeted more efficiently cells in acidic environments.
Taken together, our results indicate that ATRAM is capable of targeting cells, and this ability is
significantly greater under acidosis, without causing toxicity.

2.5. Discussion
We are currently in the midst of a golden era in the protein design field. A substantial number
of exciting successes have been recently achieved to engineer protein functions and structures
employing different computational tools (131, 132). For example, the Rosetta method allows the
de novo design of certain small soluble and membrane proteins with different functions (133, 134).
In the membrane protein field, DeGrado and coworkers have been able to computationally design
transmembrane peptides that inhibit integrins (135) as well as to create membrane helical bundles
of diverse functionalities (136, 137). However, synthetic biological elements can be created
without computationally intensive methodologies. Protein design can also be undertaken by
employing first principles and guided by experimental data. A salient example is the maquette
method of the Dutton laboratory, which allows engineering of an astounding variety of
oxidoreductase functionalities into four helix bundles (138). Upon application to membrane
proteins, it is also worth mentioning the pioneering work in which synthetic peptides were
assembled into membranes forming an ion channel (139).
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Here we wanted to design de novo a water-soluble peptide whose interaction with lipid
membranes was controlled by pH. Despite its small size, designing this kind of molecule is
challenging, because the peptide is required to be stable in environments of very different
hydrophobicities (aqueous solution and the membrane) (140). Furthermore, acidification should
efficiently trigger insertion into the membrane. While the pHLIP has been successfully applied for
imaging (141) and drug delivery across membranes (142, 143) for various solid tumors, several
features potentially restrict its use. These include modest targeting of mildly acidic tumors (141)
and a relatively strong tendency to aggregate (82). To overcome these limitations, sequence
refinement of pHLIP is desirable (144). However, progress has been hindered as a result of the
lack of solubility commonly found in single mutants of pHLIP (145). The peptide described herein
was designed to fill this need. Learning from pHLIP, we designed the ATRAM peptide with a
sequence that was only 23.5% identical to the sequence of pHLIP.
The ATRAM peptide is highly soluble in pH 8 buffer, where it remains in a largely
unstructured conformation. As projected, it is capable of binding to lipid vesicles at neutral pH,
and under acidic conditions, it forms an α-helix that aligns perpendicular to the membrane plane.
We hypothesize that a feature important for understanding the mechanism of ATRAM is the
increase in helical content associated with the coupled membrane insertion and folding (Figure
3D). In the surface bound, preinserted state, few peptide backbone hydrogen bonds are formed.
Hydrogen bonds are more energetically favored in the low-dielectric membrane core (146).
Therefore, formation of backbone hydrogen bonds integral to a TM helix will drive membrane
insertion of ATRAM. The OCD data indicate that ATRAM forms a TM α-helix at acidic pH. The
magnitude of the CD signal suggests that the TM state of ATRAM includes long disordered
stretches. It is likely that those correspond to the two ends of the sequence, while the central region
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spans the membrane. Interestingly, quantification of the CD α-helical content would suggest that
the TM region of ATRAM might be shorter than the 20 residues typically found in TM domains
(146, 147). Nonetheless, quantification of secondary structure percentages by CD is often
associated with significant errors (148). However, we are confident that the ellipticity at 222 nm
of ATRAM is compatible with a transmembrane span, because a very similar CD spectrum is
observed under conditions where pHLIP forms a TM domain (82, 144).
We Are Currently Evaluating the Directionality of the Insertion of ATRAM into
Membranes. Understanding which end of the peptide leads the membrane insertion is a
prerequisite for employing ATRAM for therapeutic purposes. We hypothesize the ATRAM
peptide will behave like the pHLIP, which inserts unidirectionally and fully translocates the Cterminal end across the membrane. This allows the pHLIP to deliver cargoes of different sizes and
polarities across the membrane (110). In case it is determined that the inserting end of the ATRAM
peptide does not fully traverse the membrane, peptide design will be optimized to elongate the
inserting end. A crucial feature of ATRAM is the use of multiple glutamic acid residues (149,
150), as the negative charges provide pH-sensing capability. Conveniently for our purposes, the
pKa values of acidic groups in hydrophobic environments are typically higher than when they are
hydrated (150, 151). Hence, while a Glu side chain has a pKa of ∼4.0 in solution, values as high

as 8.8 have been reported for Glu in different environments (152). It is then not surprising that the
pK of ATRAM resulting from the titration of Glu was 6.5, while it is 6.0 for pHLIP. In fact, the
half-unit pK difference between ATRAM and pHLIP corresponds to the pKa difference between
Glu and Asp in solution. The side chain of Glu also increases the water solubility of the ATRAM
peptide, as a result of its low hydrophobicity.
The design of membrane peptides is often complicated by their disruption of lipid bilayers. For
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example, the GALA peptide, also rich in glutamic acids, has been shown to cause
bilayersolubilization and membrane fusion (77, 80). Figure 4A shows that ATRAM does not cause
fusion or hemifusion of POPC vesicles. We also performed leakage experiments to evaluate the
integrity of the membrane, using pHLIP as a control for a nondisruptive peptide. Our data show
that the leakage observed for pHLIP, while still small, was higher than the value previously
reported (84). We attribute these differences to the high sensitivity of our calcein assay, where the
leakage value reported might be artifactually increased. For instance, in our hands, careful pipet
sample mixing resulted in calcein leakage, maybe as a result of physically stressing the vesicles.
Nevertheless, we observed similar calcein leakage for pHLIP and ATRAM except at the higher
peptide concentration, 0.7 μM. If ATRAM did in fact significantly disrupt the integrity of
membranes, we would expect it also to cause cell toxicity. However, viability studies in two
different cell lines showed that ATRAM caused no toxicity, even at a concentration (2 μM) higher
than that employed for the leakage assay, showing that the peptide is not toxic to cells in culture.
FRET experiments also showed that ATRAM forms a TM oligomer in the membrane under acidic
conditions (Figure 5B). The FRET data suggest the presence of dimers or trimers. We suggest that
ATRAM might form a dimer, because it contains GxxxG domains, which have been identified to
induce dimerization in numerous transmembrane domains (153, 154).
Two interesting works that describe different efforts to design peptides with pH-dependent
membrane insertion have recently been published. The DeGrado group computationally designed
a series of peptides and evaluated their ability to form pores in the membrane upon acidification
(70). Oligomeric assembly was achieved both in solution and in the presence of membranes, where
the peripheral state was postulated to exchange into a transmembrane pore. The groups of Hristova
and Wimley employed a different approach, decorating the lytic peptide melittin with different
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acidic residues (68). While macromolecular release across the membrane was not achieved in this
case, interestingly, the resulting peptides were able to form an α-helix in POPC vesicles in a pHdependent fashion. However, the orientation of the helix was not determined, and the pK values
were highly acidic, between 4.6 and 5.0.
Malignant solid tumors typically have an extracellular environment with a pH value of 6.5−6.9
(155), significantly more acidic than healthy tissues, where the extracellular pH is 7.2−7.4.6
Interestingly, the membrane insertion pK of the ATRAM peptide is 6.5, suggesting that it might
be effective in targeting malignant solid tumors. Our data show that the targeting of cells by
ATRAM is very efficient, and importantly, the level of targeting is significantly higher under
acidic conditions (Figure 4). Interestingly, for the A375 melanoma cells, strong targeting was
achieved at pH 5.0 and 6.0, suggesting that high acidity is not required for efficient cell targeting.
It has been previously reported that the membrane insertion pK of pHLIP differs between cells
with differing lipid compositions (156). A similar behavior might account for the observed
requirement of higher acidity for maximal ATRAM insertion in H358 cells (Figure 6B).
Interestingly, for both cell lines, we observed a higher level of targeting by ATRAM than by
pHLIP. This might be partially explained by the slightly higher lipid affinity of ATRAM. Hence,
while the POPC partition coefficient, Kp, of ATRAM at pH 8 was (5.5 ± 2.5) × 105, the Kp of
pHLIP obtained under identical conditions was (2.1 ± 0.4) × 105 (90). The targeting differences
observed between the two cell lines might also be associated with the distinct cellular distribution
for ATRAM. In H358 cells, ATRAM localizes primarily to the plasma membrane, while in A375
cells, it is also heterogeneously distributed across the cytoplasm, probably at endocytic vesicles.
We observed a similar trend for pHLIP, in agreement with a previous suggestion that pHLIP might
leave the plasma membrane because of membrane recycling and/or endocytosis (143).
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Here we show that ATRAM is soluble at high concentrations, at least up to 200 μM. This
contrasts with the case for pHLIP, for which peptide aggregation is observed above 7 μM (82).
When membranes are available, ATRAM binds to the bilayer surface, adopting a partially helical
structure that lies parallel to the membrane plane. Finally, acidity drives ATRAM to insert, forming
a transmembrane helix, which increases its affinity for membranes. The POPC insertion pK of
ATRAM was 6.5, suggesting that ATRAM might be able to target the more frequent mildly acidic
diseased tissues. The observed lack of cellular toxicity and the efficient targeting of cells in an
acidity-dependent fashion suggest that ATRAM might be a promising new tool for targeted
therapies applied to cancer and other acidic diseases.
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Chapter III. Mechanistic insights into the pH-dependent membrane
peptide ATRAM
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A version of this chapter was originally published by Vanessa. P. Nguyen, Loganathan
Palanikumar, Stephen J. Kennel, Daiane S. Alves, Yujie Ye, Jonathan S. Wall, Mazin Magzoub,
and Francisco N. Barrera in Journal of Controlled Release 2019, 298: 142-153.
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3.1. Abstract
pH-responsive peptides are promising therapeutic molecules that can specifically target the plasma
membrane in the acidified extracellular medium that bathes cells in tumors. We designed the
acidity-triggered rational membrane (ATRAM) peptide to have a pH-responsive membrane
interaction. At physiological pH, ATRAM binds to the membrane surface in a largely unstructured
conformation, while in acidic conditions it inserts into lipid bilayers forming a transmembrane
helix. However, the molecular mechanism ATRAM uses to target and insert into tumor cells
remains poorly understood. Here, we determined that ATRAM inserts into cancer cells with a
preferential membrane orientation, where the C-terminus of the peptide traverses the plasma
membrane and explores the cytoplasm. Using biophysical techniques, we determined that the
membrane interaction of ATRAM is contingent on the concentration of the peptide. Kinetic studies
showed that membrane insertion occurs in at least three steps, where only the first step was affected
by the membrane density of ATRAM. These observations, combined with membrane binding and
leakage data, indicate that the interaction of ATRAM with lipid membranes is dependent on its
oligomerization state. SPECT/CT imaging in mice revealed that ATRAM accumulates in the blood
pool, where it has a prolonged circulation time (> 4 hours). Since fast peptide clearance and
degradation in circulation are major problems for clinical development, we studied the mechanism
ATRAM uses to remain in the blood stream. Using binding and transfer assays, we determined
that ATRAM binds reversibly to human serum albumin. We propose that ATRAM uses albumin
as a carrier in the blood stream to evade clearance and proteolysis before interacting with the
plasma membrane of cancer cells. We also show that ATRAM is able to be deliver liposomes to
cells in a pH dependent way. Our data highlight the potential of ATRAM as a specific therapeutic
agent for diseases that lead to acidic tissues, including cancer.
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3.2. Introduction
Cancer nanotechnology and nano-architectonics are being intensively studied to be used as
cancer diagnosis and treatment (157, 158).

It has been shown that the accumulation of

nanoparticles in tumors have been improved due to the enhanced permeability and retention (EPR)
effect. However, the total accumulation of nanoparticles to tumors often remains low (159). To
overcome this problem, peptides have been utilized to actively target the nanoparticles to tumor
sites (160-162). Not only do peptides improve the tumor targeting of nanoparticles, they also
enhance stability (161, 163). Targeting peptides can improve the specificity and efficiency of
delivery of nanoparticles and cancer drugs, as they can selectively bind to specific targets, such as
cell surface receptors and ion channels (106, 164). Especially interesting are peptides able to
overcome the hydrophobic core of the plasma membrane, which is a major obstacle for
intracellular delivery of drugs (165, 166). The ability to fine-tune peptides according to amino
acid properties allows for targeting of distinct markers and environmental triggers. For instance,
de novo antimicrobial peptides (AMPs) are designed to be similar to natural AMPs. AMPs have a
high overall positive charge allowing them to interact with the negatively charged lipid headgroups
present in membranes of bacteria and cancer cells (167-170). Peptides can also be rationally
designed to respond to acidity. Endocytosed pH-triggered peptides can release trapped molecules,
such as drugs and siRNA, from endocytic organelles as the pH of the lumen acidifies during
endosomal maturation (67, 78, 171, 172). This is a credible way for molecules to overcome the
barrier of the cell membrane and enter the cytosol. Furthermore, there are several diseases that
result in an altered pH balance, such as inflammation and cancer (35, 173, 174). The local
extracellular pH of cancer cells can be 0.5-1 pH units lower than their healthy counterparts due to
altered glucose metabolism, vascularization, and induction of carbonic anhydrase IX, among other
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factors (91, 175, 176). This process is accentuated by the local concentration of protons on the
surface of cells, which results in a significantly more acidic pH than in the bulk microenvionment
(177, 178). Using pH-sensitive peptides as a tool to target the plasma membrane of diseased cells
can allow for higher targeting specificity of acidic diseased tissues compared to healthy ones (86,
110).
We have recently designed the synthetic pH-sensitive acidity-triggered rational membrane
(ATRAM)

peptide

(100).

ATRAM

is

a

34-amino

acid

peptide

(sequence:

GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN) that interacts with lipid bilayers in a pH
dependent manner. In neutral/basic solution, ATRAM is unstructured, but in the presence of lipid
bilayers, it partitions to the membrane surface. An acidic environment causes ATRAM to insert
gaining helical structure, forming a transmembrane helix, as determined by standard and oriented
circular dichroism(100). Insertion of ATRAM into the membrane is driven by protonation of the
acidic glutamates, which increases the overall hydrophobicity of the peptide. Biophysical
experiments showed that the membrane insertion midpoint is pH 6.5 (100). Such pH midpoint is
higher than the pKa of the Glu side chain, however this is not surprising, as the hydrophobicity of
the membrane can promote large changes in pKa (179, 180). Additional in vitro experiments
showed that ATRAM associates with melanoma and lung cancer cells more efficiently in acidic
environment than at neutral pH (100). A recent study has shown that ATRAM has a high cancer
therapeutic index in vitro (181). The therapeutic index was determined by comparing the efficacy
of amanitin toxin labeled peptide in killing cancer cells at low and physiological pH. The higher
therapeutic index indicated that ATRAM targeted cancer cells in a low pH environment more
efficiently compared to a neutral pH environment. Furthermore, it also successfully targeted
tumors in vivo, suggesting that ATRAM shows promise as a cancer therapeutics peptide (181).
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To fulfill the promise of ATRAM as a therapeutic peptide, it is fundamental to understand the
molecular mechanism ATRAM uses to interact with and insert into lipid membranes. Here, we
determined the membrane topology by evaluation of the cellular uptake of fluorescently labeled
ATRAM coupled to PEGylated liposomes. We furthermore present kinetics studies that indicate
that the membrane insertion of ATRAM involves at least two intermediates. Binding and leakage
experiments show that the interaction of ATRAM with lipid membranes is concentration
dependent. Our results suggest that ATRAM forms oligomers at the membrane surface and the
membrane interior. The degree of oligomerization importantly affects the interaction with the
membrane. Renal clearance and enzymatic degradation are often challenging in therapeutic
peptide design (182, 183). We investigated if this was the case, and observed that ATRAM was
stable in circulation 4 hours after intravenous injection. However, how ATRAM is protected from
degradation and excretion is not known. We have determined that ATRAM binds to serum
albumin, which we propose can explain the prolonged circulation of ATRAM in mice. The results
of the SPECT/CT and biodistribution studies conducted in mice support this hypothesis.

3.3. Experimental Procedures
Preparation of liposomes. Stocks of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl)
(16:0 Liss Rhod PE) (Avanti Polar Lipids Inc., Alabaster, AL) were prepared in chloroform.
Appropriate aliquots of lipids were dried with argon gas and then placed under a vacuum overnight.
Unless stated otherwise, the dried lipid films were hydrated with 10 mM NaPi (pH 8.0), and large
unilamellar vesicles (LUVs) were prepared with a Mini-Extruder (Avanti Polar Lipids, Inc.)
through 100 nm polycarbonate filters (Whatman). For the membrane orientation studies, loaded
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liposomal formulation were prepared by standard physical extrusion method following the
published literature(184). In detail, lipid mixtures of POPC/POPC-FITC (75:25) and
POPC/POPC-FITC/DSPE-PEG2000 maleimide (75:20:5) molar ratio were mixed in chloroform
and vortexed. The solvent was evaporated using nitrogen gas, and the lipid film was left in a
vacuum chamber overnight. Dry lipid was hydrated with 1 mL of 10 mM phosphate-buffered
saline (PBS) (pH 7.4) to the glass vials of lipids and agitated. Hydration time was ~0.5 hours with
vigorous vortexing. Multilamellar liposomes were obtained after resuspension, and were subjected
to 10 freeze-thaw-vortex cycles. Unilamellar liposomes were finally obtained after extruding 20
times through 100 nm polycarbonate filters. Samples were filtered before use by using a 200 nm
filter.
Labeling of peptides. For the membrane orientation studies, DSPE-PEG2000 was conjugated at
the single cysteine present at the N- or C-terminus of ATRAM (Table 2). The molar ratio between
DSPE-PEG2000-maleimide (2941.605 g/mol) to ATRAM peptide (3341.95 g/mol) was
approximately 1 (500 nM) : 20 (1 mM). In a typical synthesis, peptide was mixed with DSPEPEG2000-maleimide in of methanol and stirred overnight at room temperature, and then passed
through a Sephadex G-25 minicolumn (PD-10 columns; GE Healthcare Bio-Sciences,
Marlborough, MA) to remove the unlabeled peptides. The size of liposomes was measured by
dynamic light scattering (DLS) using a Malvern Zetasizer instrument with disposable cuvettes
right after the extrusion of liposomes. The surface charge of the liposome was – 10 mV, and size
was around 175 nm (Figure 7).
For the biophysical experiments, reactive NBD, [N, N'-dimethyl-N-(iodoacetyl)-N'-(7nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine] (Thermo Fisher Scientific, Inc., Waltham, MA)
was conjugated to a C-terminal cysteine in a Cys ATRAM variant and pHLIP (Table 2). For the
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Table 2. Sequences of peptides used
Peptide

Sequence

ATRAM

GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN

ATRAM-C*

GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELECN

ATRAM-C**

GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGNC

ATRAM-N

CGLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN

Y-ATRAM

GYAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN

pHLIP

AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG

* Biophysics experiments
** Orientation of ATRAM in cellular experiments
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A

B

Figure 7. Zeta potential (A) and size analysis (B) for ATRAM-functionalized PEGylated
liposomes.
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cell binding assay, Y-ATRAM (Table 2) was labeled at the N-terminus with 3-BODIPY-propanoyl
-aminocaproic acid N-hydroxysuccinimide ester (BODIPY FL-X; Invitrogen, Carlsbad, CA). In
all cases, free dye was removed by gel filtration through a PD-10 column, while labeled and
unlabeled peptide were separated by reverse-phase HPLC (Agilent, Santa Clara, CA). MALDITOF (Bruker, Billerica, MA) was used to confirm labeling.
Y-ATRAM was radiolabeled with
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I, by using chloramine T as the oxidizing agent. The

reaction was quenched by addition of sodium metabisulfite. Radiolabeled ATRAM peptide was
diluted in 0.1% sterile gelatin in PBS. Free radioiodine was removed through a PD-10 column
equilibrated with 0.1% gelatin/PBS. Fractions containing the maximal radioactivity were
collected. The product radiochemical purity was confirmed by SDS-PAGE and analyzed by
phosphor imaging (Cyclone Storage Phosphor System, Perkin Elmer, Shelton, CT).
Cellular uptake analysis by confocal fluorescence microscopy and fluorescence-activated cell
sorting (FACS). The membrane topology of ATRAM was assessed by measuring cellular uptake
with microscopy and flow cytometry. Human breast cancer MCF-7 cells (ATCC no. HTB-22)
were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin (all from Sigma) in 5% CO2 at 37 °C. Once the cells reached ~ 95% confluence, they
were split (using 0.25% trypsin-EDTA, Sigma) into fractions and propagated or used in
experiments. Cells were seeded at a density of 2 ×104 cells/well in 500 μL complete medium in 4
well cell-view glass bottom culture dish (Greiner bio-One, Germany) for confocal microscopy or
6-well plates for FACS. After culturing for 24 h, the cells were washed and the medium was
replaced with fresh phenol red- and serum-free medium (pH 6.5 or pH 7.4) containing 10 µM
FITC-labeled liposomes (L), PEGylated liposomes (PL), PEGylated liposomes-ATRAM Nt (PLAN) or PEGylated liposomes-ATRAM Ct (PL-AC), and incubated for 1 h. Finally, the medium
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was once again replaced with fresh medium to remove any extracellular liposomes. Cells were
imaged on an Olympus Fluoview FV-1000 confocal laser scanning microscope, with a 63× PlanApo/1.3 NA oil immersion objective with DIC capability. Images were processed using the Fiji
software(185). Uptake was quantified by FACS using a BD FACSAria III cell sorter (BD
Biosciences, San Jose, CA) (10,000 cells/sample, gated on live cells by forward/side scatter and
propidium iodide exclusion). Analysis was performed with the BD FACSDiva software.
Stopped-flow fluorescence. The intermediates of the transition from the surface bound state of
ATRAM to its transmembrane state was followed by stopped-flow fluorescence. Lyophilized
NBD-labeled ATRAM (ATRAM-NBD) was hydrated in 10 mM NaPi pH 8.0 and incubated with
POPC vesicles for one hour at lipid-to-peptide molar ratios of 200:1, 400:1, or 600:1. The lipidpeptide samples were mixed at a 1:1 volume ratio with 100 mM sodium acetate pH 3.6 (inserted
state) or 100 mM sodium phosphate pH 8 (peripheral state) to reach a final peptide concentration
of 0.1 μM. Fluorescence spectra were recorded on a SX20 Stopped-Flow instrument (Applied
Photophysics, Inc., Surrey, United Kingdom) with a 505 nm cut-off filter at 25°C. The excitation
wavelength was set to 488 nm. The data of the peripheral state were subtracted from the inserted
state to account for potential photo-bleaching and light scattering (186). Subtracted data were
analyzed with a three-exponential model using the following equation:
Signal = −A1 × exp(−𝑘𝑘1 × x) − A2 × exp(−𝑘𝑘2 × x) − A3 × exp(−𝑘𝑘3 × x) + Fo (3),

where A is the amplitude of the signal, k is the rate constant, x is time, and Fo is the offset (186).
Sulforhodamine B leakage assay. The membrane disruption behavior of ATRAM was monitored
by sulforhodamine B leakage assay in liposomes. A dried POPC lipid film was rehydrated with 20
mM sulforhodamine B (SRB) in 10 mM sodium phosphate pH 8. Large unilamellar vesicles were
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prepared as described above but using 200 nm filters. Non-encapsulated SRB was removed by gel
filtration through a PD-10 column (GE Healthcare Life Sciences). A constant amount of peptide
was added to the SRB-LUV suspensions at different initial concentrations to cover a range of
peptide:lipid mole ratios. Samples with either 10 mM sodium phosphate pH 8 or 1.5% Triton X100 were prepared as controls. After a 1-hour incubation at room temperature, the pH was altered
with 100 mM sodium acetate pH 4.1 or maintained with 100 mM sodium phosphate pH 7.5. The
samples were measured after an additional 1-hour incubation. The change in fluorescence
intensity was measured using a Cytation 5 microplate reader (Biotek Instruments, Inc., Winooski,
VT) with an excitation wavelength of 550 nm and emission wavelength of 590 nm. SRB leakage
was calculated with the following equation:
% Leakage = 100 ×

(𝐹𝐹−𝐹𝐹𝑚𝑚𝑚𝑚𝑚𝑚 )

(𝐹𝐹𝑚𝑚𝑚𝑚𝑚𝑚 −𝐹𝐹𝑚𝑚𝑚𝑚𝑚𝑚 )

(4),

where F, Fmax, and Fmin are the measured fluorescence intensities of SRB-POPC vesicles with
peptide, Triton X-100, and buffer, respectively (187).
NBD lipid binding assay. To determine the effect of peptide concentration on membrane affinity,
the partition coefficient was determined at different peptide concentrations. Lyophilized ATRAMNBD was hydrated in 10 mM NaPi pH 8.0 and incubated with increasing concentration of POPC
vesicles at a final peptide concentration range of 0.125 – 0.8 μM and identical ranges of lipid-topeptide ratio with a maximum of 500:1. The pH of the samples was changed with 100 mM sodium
acetate pH 4 or 100 mM sodium phosphate pH 7.5. This was repeated with pHLIP-NBD with final
peptide concentrations of 0.1375 μM and 0.55 μM. Fluorescence spectra were recorded at 25°C
with excitation at 470 nm and an emission range of 520-600 nm, using a Cytation 5 imaging plate
reader. Fluorescence data (F) were normalized to the highest value of each individual isotherm and
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were fitted with:
Kp ×[L]

F = Fo + ∆F × 55.3+Kp ×[L] (5),
where Fo is the initial fluorescence intensity, ΔF is the change between the initial and final
fluorescence intensity, [L] is the lipid concentration, Kp is the partition coefficient, and 55.3 is the
molar concentration of water(188). Experiments with a fitting R-squared of less than 0.8 were not
included due to poor fitting. All the normalized data of their respective conditions were overlaid
and fitted using Eq. 5 to calculate the partition coefficient.
pK determination. The effect of peptide concentration on the pK of insertion was assessed by pHtitrations experiments. ATRAM-NBD was incubated with POPC vesicles at a 1:200 molar ratio
and final peptide concentrations of 0.4 and 0.8 μM. The pH of the samples was adjusted
accordingly with 100 mM buffers (sodium acetate, MES, HEPES, or sodium phosphate).
Fluorescence emission spectra were acquired at the excitation wavelength of 480 nm. The
excitation and emission slits were set to 3 nm. Measurements were performed on a Photon
Technology International Quanta Master fluorometer (Edison, NJ). Appropriate lipid backgrounds
were subtracted in all cases. The data were analyzed following the fluorescence intensity at 525
nm, which were then fitted to determine the pK, using:
𝐹𝐹 =

𝐹𝐹𝑎𝑎 +𝐹𝐹𝑏𝑏 ∗10𝑚𝑚(𝑝𝑝𝑝𝑝−𝑝𝑝K)
1−10𝑚𝑚(𝑝𝑝𝑝𝑝−𝑝𝑝K)

(6),

where Fa is the acidic baseline, Fb is the basic baseline, m is the slope of the transition, and pK is
the midpoint of the curve.
Serum albumin binding assay. To determine the possibility of ATRAM using serum albumin as
a carrier molecule, a binding assay were performed. Human serum albumin (HSA, ≥96% purity,
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Sigma-Aldrich) and ATRAM-NBD were prepared in PBS. A constant concentration of peptide
(0.4 μM) was added to a range of increasing concentrations of HSA (0.25-15 μM). The peptide
concentration was chosen from the results of the lipid binding assay. The selected concentration
(0.4 μM) was the lowest concentration where the peptide concentration had no effect on the
partition coefficient. The concentration range of HSA was picked due to the binding curve
achieving saturation. Fluorescence anisotropy was measured on Photon Technology International
Quanta Master fluorometer at room temperature with the excitation and emission wavelengths set
to 460 and 535 nm, respectively. The excitation and emission slits were set to 6 nm. The
dissociation constant (Kd) was determined using the following equation:

< r >=< r >𝑏𝑏 + (< 𝑟𝑟 >𝑓𝑓 −< 𝑟𝑟 >𝑏𝑏 )

([L]+Kd +[P])−�([L]+ Kd +[P])2 −4[L][P]
2[P]

(7),

where <r> is the measured anisotropy, <r>f and <r>b are the anisotropy for the free and the
completely bound fluorescent ligand, respectively. [L] and [P] represent the total fluorescent
ligand (ATRAM-NBD) and protein (HSA) concentration, respectively (189, 190).
Vesicle transfer assay. The spontaneous transfer of ATRAM from human serum albumin to
membrane vesicles was measured using a fluorescence transfer assay. Human serum albumin,
POPC and ATRAM-NBD were prepared in PBS. ATRAM-NBD was incubated with POPC or
HSA for 1 hour with a final peptide concentration of 0.5 μM at pH 7.4. The final molar ratio of
lipid to peptide was 250:1, while the molar ratio of HSA to peptide was 10:1. Additionally, POPC
was added to the samples containing the peptide-HSA mixture and incubated for 1 hour. The final
concentrations were kept constant. Fluorescence spectra were measured on a Photon Technology
International Quanta Master fluorometer at room temperature with the excitation wavelength set
to 460 nm, and the emission wavelength ranging from 490 to 630 nm. The excitation and emission
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slits were set to 6 nm. Anisotropy values were measured on a Horiba Fluorolog-3
spectrofluorometer (Edison, NJ) at room temperature with the excitation wavelength set to 460
nm, and the emission wavelength set to 535 nm. The excitation and emission slits were set to 6
nm. Appropriate blanks were subtracted.
pH-dependent cell binding. To determine whether the addition of tyrosine had an effect on the
pH-dependency of the peptide in cells, pH-dependent cell binding experiments were performed
with Y-ATRAM. H358 cells, obtained from ATCC, were cultured in a humidified incubator under
5% CO2 in RPMI medium supplemented with 10% of Fetal Bovine Serum, 50 U/mL penicillin,
50 μg/ml streptomycin (Invitrogen). Two days prior the experiment, cells were plated at a seeding
density of 1 x 104 cells per well in a 96-well black collagen-coated plate (Corning, Corning, NY).
The binding assay was performed by washing cells twice with PBS supplemented with 1 mM
MgCl2 and 100 μM CaCl2 (PBS++) and incubating with 2 μM BODIPY labeled Y-ATRAM for 5
min. After a 90 s incubation with PBS++ containing 10 mM dextrose (Sigma-Aldrich) at different
pH values, cells were washed one time in the same pH buffer, and then fixed with 4%
paraformaldehyde for 30 min. Fluorescence intensity at 488 nm was detected in a plate reader
(Synergy 2, Biotek). The quantification analysis is a result of three independent experiments
performed in triplicate.
SPECT/CT imaging. To visualize the biodistribution of ATRAM in mice, SPECT/CT imaging
was performed as described elsewhere (191). Briefly, Balb/c mice from a colony maintained at
UTMC, females between 8 and 12 weeks of age, mice (n = 3) were injected with ~5 µg of

125

I-

ATRAM, ~80 µCi in the lateral tail vein. The mice were euthanized after an uptake time of either
1 h or 4 h by isoflurane inhalation overdose. SPECT images were attained using an Inveon
trimodality imaging platform (Siemens Preclinical Solution, Knoxville, TN). CT data were
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obtained using an X-ray voltage biased to 80 kVp with a 500 mA anode current, with 4 x 4 binning.
SPECT and CT images were visualized with the Inveon Research Workplace visualization
software package (Siemens Preclinical Solution, Knoxville, TN).
Tissue biodistribution measurements. To support the SPECT/CT data, biodistribution
measurements were performed as described previously (191). Briefly, from every mouse that was
imaged with

125

I-ATRAM, samples of heart, kidneys, intestines, spleen, liver, pancreas, and

stomach were harvested post mortem. Each sample was weighed, and the 125I radioactivity was
measured using an automated Wizard 3 gamma counter (192) (1480 Wallac Gamma Counter,
Perkin Elmer).
Microautoradiography.

Similar

to

the

tissue

biodistribution

measurements,

microautoradiography was performed to support the SPECT/CT data. Each tissue sample was
fixed in 10% buffered-formalin and embedded in paraffin. Then, 6-μm-thick tissue sections were
dipped in NTB-2 emulsion (Eastman Kodak), stored in the dark, and developed after a 4-day
exposure. Each section was counterstained with hematoxylin and eosin.
Peptide stability in serum. To study the stability of the peptide in serum, a concentrated stock of
ATRAM-NBD (300 μM) was diluted in fetal bovine serum for different times and incubated at
37°C. ATRAM-NBD was separated from serum proteins using chloroform/methanol, and the
solvents were dried, and resuspended in methanol for HPLC. We used a StableBond Analytical
Agilent Zorbax 300 SB-C18 column on an Agilent 1200 series HPLC system (Santa Clara, CA).
The gradient from solvent A (H2O + 0.05% TFA) to solvent B (methanol + 0.05% TFA) started
with a 15 minute gradient from 5% B to 80% B followed by a 35 minute gradient from 80% B to
100% B and ended with a 5 minute gradient back to 5% B. Flow rate was set to 2mL/min.
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3.4. Results
Cellular studies of the orientation of ATRAM membrane insertion. The establishment of the
TM helix of ATRAM requires only one peptide end to insert across the membrane. However, it is
not known if the insertion has a preferred orientation. To determine the directionality of the
membrane insertion of ATRAM, we developed an assay where either the Ct or Nt of ATRAM were
conjugated to a large particle, which is expected to block membrane insertion through the that
peptide end. Specifically, we conjugated either the Nt of ATRAM (PL-AN) or the Ct of ATRAM
(PL-AC) separately to the PEGylated liposome (PL). We initially studied ATRAM insertion in
MCF7 human breast cancer cells using fluorescence-activated cell sorting (FACS). We used
fluorescent (FITC)-labeled lipids to detect any liposome attachment to the cells mediated by
ATRAM. After cell incubation with PL-AN at neutral pH, most cells were not labeled, and only a
small population was weakly fluorescent (Figure 8A). However, when the experiment was
repeated at pH 6.5, a pH close to the extracellular acidity of tumors (33, 91), most cells were
labeled and with higher intensity. Control experiments showed that use of PEGylated liposomes
devoid of ATRAM (PL), or standard liposomes (L), did not induce significant labeling at either
pH value (Figure 8C). When the experiment was repeated with ATRAM conjugated with PL at
the other peptide terminus, PL-AC, weak cell labeling was obtained at either pH (Figure 8B).
These results suggested that when the Ct of ATRAM is available to insert into membranes (PLAN), acidity-triggered cell insertion is observed. However, a basal insertion was also observed in
all conditions when ATRAM was present. This observation suggested the presence of a secondary
cellular incorporation mechanism, such as endocytosis.
Next, the cellular uptake of the liposomes (L, PL, PL-AN and PL-AC) was investigated
using confocal laser scanning microscopy. FITC-labeled liposomes were visualized in MCF7 cells
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Figure 8. Membrane orientation of ATRAM insertion in cells. (A-C) Quantification of cellular
attachment by fluorescence-activated cell sorting (FACS). FACS analysis of MCF-7 cells treated
with FITC-labeled PEGylated liposomes conjugated to (A) Nt (PL-AN) or (B) Ct (PL-AC)
ATRAM at pH 6.5 or 7.4 were compared to background fluorescence of untreated controls. (C)
Summary of the FACS data for MCF-7 cells treated with FITC-labeled liposomes (L), PEGylated
liposomes (PL), PL-AC or PL-AN at pH 6.5 or pH 7.4. Mean values are shown ± S.D. Statistical
analysis was carried out using the Student’s t-test (n = 3). *P < 0.05; **P < 0.001 compared with
their control group.
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after incubation for 1 hour at pH 6.5 or 7.4. In agreement with the FACS data, fluorescence was
more intense in cells incubated with PL-AN compared to PL-AC at pH 6.5 (Figure 9F). In both
cases, the fluorescence signal was observed at the plasma membrane but also in an intracellular
distribution suggesting endosomal localization (Figure 8D). At pH 7.4, a weaker intracellular
fluorescence signal was detected for both PL-AC and PL-AN (Figure 9C/E). Taken together, the
cellular results suggested that i) the C-terminal end of ATRAM inserts into cell membranes in a
pH-dependent fashion, and that ii) endocytosis is a secondary nonspecific cell incorporation
mechanism, albeit weaker in our experimental conditions (Figure 9G).
Membrane insertion kinetics. To gain needed insights on the membrane folding and insertion
pathway of ATRAM, we completed stopped-flow fluorescence kinetic experiments in vesicles,
where we monitored the transition of the peptide from the peripheral state to the transmembrane
state (186). To do this, we incubated NBD-labeled ATRAM with POPC vesicles at neutral pH for
one hour. Next, samples were rapidly mixed with acidic buffer (pH 4) to trigger the formation of
the transmembrane state, and we followed the fluorescence intensity change of the
environmentally sensitive NBD dye. We observed that the fluorescence signal increased rapidly
to a maximum before decaying slightly, and then finally slowly increasing again (Figure 10A). To
establish the best fit for the stopped-flow fluorescence data, we used kinetic models with zero to
two intermediate states. The two-intermediate model had the fewest intermediates that had uniform
residuals (Figure 11). This suggested that the peptide insertion process has at least two intermediate
states. These stopped-flow experiments were performed at 400:1 lipid-to-peptide mole ratio. We
repeated this experiment at a lower and higher lipid-to-peptide mole ratio (200:1 and 600:1). When
comparing the three rate constants, we noticed that the first rate constant was significantly affected,
but not the slower second or third constant (Figure 10B and Table 3). Thus, we observed that by
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Figure 9. Membrane orientation of ATRAM insertion in cells. (A-F) Assessment of cellular
uptake by confocal fluorescence microscopy. Images of MCF-7 cells following incubation with
FITC-labeled (D) liposomes or (E) PEGylated liposomes. Cells treated with FITC-labeled
PEGylated liposomes conjugated to (F-G) PL-AC or (H-I) PL-AN of ATRAM at pH 7.4 and pH
6.5, respectively, 1h. Scale bar = 10 µm. (G) Schematic description of the efficient internalization
by PL-AN compared to PL-AC at the acidic peritumoral pH condition. PL-AN internalization is
high, whereas the PL-AC had lower uptake. Image is not to scale and PEG is not shown.
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A

B

Figure 10. Kinetics of ATRAM-NBD insertion in POPC bilayers. (A) Insertion of ATRAM
from the peripheral to the inserted state was followed by stopped-flow fluorescence (400:1
lipid:peptide mole ratio). Curves were fitted to a three exponential model (Eq. 4), indicating at
least 2 intermediates. (B) The three rate constants are shown as k1 (black), k2 (red), and k3 (blue).
The experiment was repeated with 200:1 and 600:1 lipid:peptide mole ratios. Mean values are
shown ± S.D. (n = 3-4) (**, p < 0.01; NS, non-significant from ANOVA).
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A

B

C

Figure 11. Averaged stopped-flow spectra of ATRAM in POPC upon rapid mixing at (A) 200:1
(n = 4), (B) 400:1 (n = 4), (C) 600:1 (n = 3) lipid:peptide mole ratios. Below the fluorescence data
are the residuals of the three different exponential (Top to bottom: Residuals of three exponential
to one exponential model). The fitting of exponential model was only accepted if the residuals
were fully uniform. Red lines in top panels correspond to three exponential fitting.
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decreasing the peptide density on the membrane (600:1), the first step occurred more rapidly. The
peptide density here is describing the amount of available peptide for the total lipid area and does
not refer to the fraction of peptide bound to the lipid. The observed density-dependence might
reflect repulsion effects or changes in the oligomerization state of ATRAM. To investigate the
later possibility, we performed additional biophysical studies over a range of ATRAM
concentrations.
Membrane leakage is dependent on the oligomerization state. To gain more information about
the oligomerization of ATRAM at/in the membrane, we performed a sulforhodamine B leakage
assay. The assay was carried out at a constant POPC concentration and a range of ATRAM
concentrations (0.00325-1.7 μM). Decreasing the lipid-to-peptide ratio from ~26000:1 (0.00325
μM ATRAM) to 200:1 (0.5 μM ATRAM) resulted in an increase in leakage at both low and high
pH (Figure 12A). However, after 200:1 lipid-to-peptide ratio at the high ATRAM concentrations,
the amount of leakage decreased at both low and high pH. We also represent the leakage as
function of peptide concentration (Figure 12B). We observed significant leakage (defined as
>10%), at 13nM ATRAM and pH 8, and 52 nM at pH 4. Leakage decreased once the peptide
concentration was higher than 0.5 μM. The trend of SRB leakage at pH 4 was similar to pH 7.5; it
increased until ~0.5 μM, then the leakage started to decrease (Figure 12B). This showed that lower
ATRAM concentrations were required for maximum leakage, while at higher concentrations,
where increased ATRAM oligomerization was expected, the interaction with the membrane
changed.
Affinity to lipid membranes is concentration dependent. The partition coefficient (Kp) defines
the relative affinity between the solution and the bilayer phase (187). To determine if the lipid
partition coefficient of ATRAM was also contingent on peptide concentration, we performed
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Table 3. Stopped-flow rate constants and amplitudes
-1

-1

-1

Lipid:Peptide

k1 (s )

k2 (s )

k3 (s )

A1 (a.u.)

A2 (a.u.)

A3 (a.u.)

200:1

1.65±0.21

0.32±0.07

0.03±0.01

1.20±0.16

-0.23±0.04

0.23±0.04

400:1

2.28±0.11

0.31±0.03

0.03±0.003

1.55±0.25

-0.41±0.09

0.33±0.06

600:1

3.17±0.40

0.32±0.09

0.02±0.002

1.19±0.33

-0.46±0.16

0.15±0.07

Data is shown as mean ± S.D. (n = 3-4)
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A

B

Figure 12. ATRAM concentration affects POPC membrane disruption. (A) The fluorescence
intensity of sulforhodamine B (SRB) encapsulated in POPC vesicles was monitored after the
addition of ATRAM (0.0025− 2 mol %) at pH 7.5 (blue) and pH 4 (red). Complete leakage was
achieved on addition of Triton X-100. Mean values are shown ± S.D. (n = 3). (B) shows the same
data presented with the concentration of ATRAM in the x-axis scale.
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binding experiments at two ATRAM concentrations (0.25 and 0.8 μM) at pH 4, corresponding to
the transmembrane state. We observed that ATRAM bound more readily to POPC at 0.25 μM than
at 0.8 μM (Figure 13A). When we systematically repeated the binding experiments over a range
of peptide concentrations (0.125-0.8 μM) (Figure 14), we observed that at increasing ATRAM
concentration, the Kp decreased more than 10-fold (note the logarithmic scale in Figure 13B) and
finally leveled off around 0.5 μM. A similar decrease in affinity was also observed at physiological
pH. In ideal conditions Kp should not depend on the concentration of ATRAM. However, as the
partition coefficient is changing with concentration of the peptide, the binding is considered
nonideal, and the true partition coefficient cannot be determined (188, 193). Therefore, the
reported partition coefficient will be referred to hereafter as the apparent Kp (Kapp) (188). As shown
earlier at a single ATRAM concentration, the apparent partition coefficient was consistently higher
in the transmembrane state (acidic pH) than the peripheral state (neutral pH) (100). This result is
not surprising as the four glutamates present in ATRAM would be protonated at pH 4, which
increases the hydrophobicity and, in turn, the membrane affinity of the peptide. We wanted to
investigate if a change in oligomerization could cause the Kapp changes observed at neutral pH. To
this end we repeated the experiment with pHLIP, which is monomeric at both acidic and neutral
pH under our experimental conditions (194). We observed that pHLIP also showed higher POPC
affinity at low concentrations, indicating that a factor other than a change in oligomerization state
is responsible for the Kapp changes in ATRAM. This raised the possibility that the pK, which
reports on membrane insertion, varies at different concentrations. To explore this possibility, we
measured the pH-dependent change in the fluorescence intensities of NBD labeled ATRAM at two
concentrations, 0.4 and 0.8 μM (Figure 15). The obtained pK values were 6.67 ± 0.12 and 6.66
±0.18, respectively. The pK could not be accurately determined at concentrations lower than 0.4
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A

B

Figure 13. Peptide concentration affects the adsorption of ATRAM to POPC vesicles. (A)
Representative POPC binding assay of ATRAM-NBD at pH 4 with final peptide concentrations
of 0.25 μM (closed symbols) and 0.8 μM (open symbols). The fluorescence intensities were
normalized to the maximal value. Curves were fitted to Eq. 5 to determine the partition coefficient
(Kp). (B) Kapp varies as a function of ATRAM concentration at both acidic (red) and physiological
pH (blue), which was also observed with pHLIP at physiological pH (black). Mean values are
shown ± S.D. (n = 4).
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Figure 14. Representative fluorescence emission spectra of ATRAM-NBD at 0.8 μM (A/D) and
0.125 μM (B/E), at pH 4 (A-B) and pH 7.5 (D-E). Representative Kapp binding curves at pH 4
(C) and pH 7.5 (F) which were fitted to Eq. 5.
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µM due to poor signal. Our data suggested that oligomerization changes did not affect the steadystate pH-dependent membrane insertion of ATRAM.
ATRAM binds to human serum albumin. One of the biggest challenges of therapeutic peptides
injected intravenously is their rapid clearance from circulation due to renal filtration and
proteolytic degradation (183, 195). Notably, ATRAM is able to target tumors efficiently in mice
(181). However, it is not known how the peptide is able to evade proteolysis and clearance. We
hypothesized ATRAM might avoid those processes due to being protected by binding to serum
albumin. To test this possibility, we measured the change in anisotropy of NBD labeled ATRAM
in the presence of human serum albumin (HSA). Upon HSA incubation, we observed a saturating
increase in anisotropy, expected to result from a decrease in the tumbling rate of the HSA-bound
fluorescent peptide. From the resulting isotherm, we determined that ATRAM binds to HSA with
an affinity (KD) of 1.13 ± 0.37 μM (Figure 16A). This result suggested that albumin binding might
be the mechanism ATRAM uses to avoid fast proteolysis and clearance in the blood stream.
Our data suggest that when ATRAM is injected into the blood stream, it can use serum albumin
as a temporary carrier until it reaches its target. However, to concentrate within tumors, the peptide
would need to first unbind albumin to gain access to the membrane of cancer cells. We performed
a fluorescence assay to study if there was transfer of ATRAM from HSA to membranes (POPC
vesicles) (Figure 16B) (196, 197). The assay used NBD as an environmentally sensitive probe that
responds to the presence of water (198, 199). The fluorescence intensity of NBD increases upon
moving from a fully hydrated to a less polar environment, such as those in the HSA binding site
or lipid membranes. When ATRAM-NBD binds to HSA, we observed an increase in fluorescence
intensity compared to peptide in solution (Figure 16C). This agrees with the increase in anisotropy
observed in Figure 16A. The fluorescence of NBD increased to a larger extent when the peptide
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Figure 15. ATRAM concentration does not affect the insertion pK into POPC vesicles.
Representative pH titration curves obtained by monitoring the fluorescence intensity changes of
ATRAM-NBD at 525 nm (n = 4). The final concentrations of ATRAM were 0.4 μM (closed
symbols) and 0.8 μM (open symbols). The black lines are the fittings to Eq. 6 to determine the pK.
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E

Figure 16. Lipid membranes compete with human serum albumin for ATRAM binding. (A)
Representative binding curve of ATRAM-NBD to human serum albumin measured by
fluorescence anisotropy. The curve shows the fitting obtained with Eq. 7 to determine the
dissociation constant (KD). (B) Flow chart of the experimental steps to study the interaction of
ATRAM with HSA and lipid vesicles. (C) Representative fluorescence spectra of ATRAM-NBD
in solution (blue), bound to POPC (black), HSA (red), or bound to HSA with the addition of POPC
(green). (D) Anisotropy values of ATRAM-NBD bound to POPC (black), HSA (red) or bound to
HSA with the addition of POPC (green). Mean values are shown ± S.D. (n = 3-4; ***, p < 0.001;
*, p < 0.05 from ANOVA). (E) Model of ATRAM (red) reversibly interacting with human serum
albumin (dark grey; PDB 1AO6) and lipid membranes (light grey). It is not known at which exact
site ATRAM binds to HSA. Molecules are not to scale.
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was bound to POPC vesicles. The differences in fluorescence intensity of ATRAM-NBD upon
binding to either POPC or HSA likely occur due to the environment of the lipid being less solvated
than the HSA binding site for ATRAM. We studied next the potential transfer of ATRAM from
HSA to membranes. Thus, ATRAM-NBD was preincubated with saturating levels of HSA, and
then POPC vesicles were added. An increase in fluorescence intensity was observed compared to
ATRAM-NBD in the presence of only HSA (Figure 16C), which suggested that ATRAM can
unbind HSA to bind vesicles. However, since the fluorescence intensity was significantly lower
than ATRAM-NBD in the presence of only POPC, this suggest that a fraction of ATRAM-NBD
still remains bound to HSA in the presence of POPC vesicles at neutral pH.
Additional anisotropy experiments were performed under the same conditions to confirm the
findings (Figure 16D). ATRAM-NBD in the presence of HSA had a <r> value of 0.27 while in
POPC vesicles the <r> value was 0.19. An intermediate anisotropy was observed after POPC was
added to the ATRAM-NBD/HSA sample (<r> = 0.22). This confirms that ATRAM-NBD does
interact with reversibly with HSA (Figure 16E), and in our experimental conditions, a fraction of
ATRAM-NBD unbinds HSA in the presence of POPC.
ATRAM biodistribution by imaging. Having shown that ATRAM binds to serum albumin in
vitro, we wanted to study if it could correlate to a prolonged circulation half-life in vivo. Thus, we
injected the peptide into wild type mice to confirm that the peptide does not undergo fast
proteolysis and to study its biodistribution. To this end, a variant of ATRAM was radioiodinated
with iodine-125 (125I). Iodine-125 was incorporated into tyrosine residues under oxidative
conditions (200, 201). As ATRAM does not have a tyrosine residue, we used an ATRAM variant
(Y-ATRAM) where a leucine at the N-terminus was replaced with a tyrosine residue (Table 2).
To ensure that the tyrosine residue does not affect the pH-responsive properties of ATRAM in
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vitro, fluorescence was used to monitor the association of BODIPY-labeled Y-ATRAM with H358
cells. After a brief incubation with the peptide, cells were rinsed with solutions of differing pH,
and the fluorescence signal was evaluated. Similar to WT ATRAM, Y-ATRAM associated with
cells in a pH-dependent manner with stronger interactions in acidic environments compared to
neutral ones (Figure 17) (100), validating the use of this peptide variant.
The biodistribution of 125I-ATRAM in wild type (WT) mice was examined by SPECT/CT imaging.
Figure 18A revealed a characteristic pattern of blood pool, with high activity in the liver and heart
at both 1 and 4 hours post-injection (pi). The liver and heart were both visible 4 hours pi,
suggesting that there is still considerable 125I-ATRAM in the circulation. Axial views, at both time
points, were taken through the plane of the liver and demonstrate intense activity in this organ that
persists for at least 4 hours pi. Similarly, high activity was observed in the thyroid and stomach.
As radiolabeled peptide was injected intravenously, it would be eventually taken up by the kidneys
and undergo catabolism and dehalogenation (202, 203). As shown in Figure 18A, this
consequently led to the sequestration of radioiodine, and thus radioactivity of the thyroid and
stomach were of equivalent intensity as the liver. At 4 hours pi, radioiodine levels decreased in the
stomach due to emptying and gastrointestinal excretion of iodide. In contrast, the thyroid gland
activity became more intense due to increased accumulation of the

125

I because radioiodine is

organified and will remain permanently in the thyroid (204). Further examination indicated that
there was no SPECT/CT evidence of accumulation of 125I-ATRAM at other organs and tissues. As
we have shown in our biophysical experiments, lower ATRAM concentrations show higher
membrane affinity and decreased membrane disruption. This could suggest that a lower
concentration needs to be injected into the bloodstream to be effective.
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Figure 17. Y-ATRAM-BODIPY binds to cells in a pH dependent fashion. Similarly to
ATRAM (100), Y-ATRAM showed a stronger binding at more acidic pH. **, p < 0.01.
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Figure 18. Distribution of 125I-ATRAM mice. (A) Whole body biodistribution of radioactivity
by SPECT/CT in mice injected IV at 1 h and 4 h post injection shown from the coronal, sagittal,
and axial views. Radioactivity is false-colored red/yellow. (B) Tissue biodistribution of 125IATRAM in wild type (WT) mice at 1 h and 4 h post injection. Bars represent mean % injected
dose per gram of tissue (%ID/g) ± S.D. (n = 3). Up. Int., upper intestine; Low. Int., lower intestine.
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Tissue biodistribution of

125I-ATRAM

performed to quantify the amount of

125

radioactivity. Tissue radioactivity measurements were

I-ATRAM in various organs and tissues. Activity in the

kidneys was observed, as expected, since they are the major site of protein dehalogenation in mice.
Similar to the SPECT images, the liver was found to have the highest levels of radioactivity at
both 1 h (18% ID/g) and 4 h (10% ID/g) pi (Figure 18B). This suggests that 125I-ATRAM binds to
components in the blood, which at some point is present at the liver. One of these components is
believed to be serum albumin, since our in vitro data show that ATRAM binds to HSA (Figure
16). Furthermore, albumin, the most abundant plasma protein, at a concentration of 40-50 mg/ml
(95, 205), is synthesized in the liver. The tissue biodistribution data also confirmed the presence
and persistence of

125

I-ATRAM in the heart, which represents the sum of activity in the

myocardium and any blood trapped in the ventricle that was taken for tissue measurement. The
spleen, pancreas, and intestines samples were all unremarkable relative to the liver, heart, and
kidneys. Lungs were heavily trapped, as expected from the high levels of albumin in capillaries as
well as in the pulmonary interstitium (206).
Microautoradiography was used to study the microscopic distribution of 125I-ATRAM within
organs and tissues. The presence of radiolabeled peptide is evidenced by the deposition of black
silver grains in the autoradiographs. Corresponding to the imaging and tissue distribution studies,
there was significant accumulation of 125I-ATRAM in the liver at both time points. The distribution
was not focal, suggesting that there was no accumulation within cells. The distribution appeared
diffuse but intense in the sinusoids and perivascular regions (Figure 19). The peptide was visible
in the tubular lumen of the kidneys and associated with the vasculature and regions of the blood
pool. In addition to evidence of

125

I-ATRAM in the blood pool, there was evidence of modest

levels of ATRAM in the myocardium. These organs were juxtaposed to the spleen, where little or
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Figure 19. Microautoradiographs of tissue from WT mice injected IV with 125I-ATRAM peptide
at 1 hour and 4 hours post injection. Radiolabeled peptide is evidenced by the presence of black
silver grains. Original magnification = 80x.
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no activity was observed at either time point. Overall, the radioisotopic studies performed in mice
agree with our hypothesis that ATRAM binds to a blood component as a carrier in vivo, which we
suggest is albumin.
Proteolytic cleavage of peptides often compromises their successful therapeutic application
(207). We hypothesized that the binding of ATRAM to albumin might provide increased resistance
to proteases. To evaluate this, we studied the stability of ATRAM in fetal bovine serum (FBS) at
37°C. We observed no noticeable peptide degradation after 17 hours of FBS incubation (Figure
20). This result might help explaining the promising biodistribution data.

3.5. Discussion
Targeted therapies have the potential to provide more effective and selective treatment for cancer.
However, to fulfill this promise we first need to understand the mechanism that molecules use to
attain adequate pharmacodynamics and pharmacokinetics, as well as specific targeting of diseased
cells. ATRAM was designed to use the acidity prevalent in aggressive tumors (35, 91, 174, 175)
to trigger membrane insertion, which is useful for drug delivery and imaging applications (100).
ATRAM exhibits promising properties for targeting tumors (181). In this work we carried out
experiments that advanced the knowledge of the molecular basis of the action of ATRAM. While
previous studies were performed with drugs conjugated at the C-terminus of the peptide (181), it
was still not known whether membrane insertion occurs through this end or if the insertion is unidirectional. With flow cytometry and microscopy studies, we have determined that ATRAM does
indeed insert into cells with its C-terminus in a unidirectional fashion (Figure 8 and Figure 9).
However, we observed partially punctate patterns of intracellular fluorescence observed in the
confocal microscopy images. This is often indicative of localization to endosomal compartments,
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Figure 20. Serum stability of ATRAM conjugated with NBD. (A) HPLC chromatograms
obtained for free NBD dye and extracted ATRAM-NBD at t=0 h, and t=23 h are shown. Vertical
axis shows the NBD absorbance (488 nm), and the horizontal axis the elution time in minutes (m).
The HPLC gradient starts at 15 m and ends at 50 m. (B) The ATRAM-NBD peak eluting at 26 m
was quantified, and the normalized concentration is shown for different serum incubation times
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and suggests that the peptide not only is inserted at the plasma membrane but is also partly taken
up by endocytosis. These studies also demonstrate that ATRAM can deliver larger molecules, in
this case liposomes, to cells in a pH dependent manner.
When ATRAM is in a membrane-adsorbed state, a pH decrease induces a conformational
change that results in the formation of a transmembrane α-helix (100). However, it was not known
if this process involved the presence of intermediate states. A simple two-state model cannot
adequately fit the stopped-flow data shown in Figure 10A. Instead, a triple exponential equation
is required to fit the data (Figure 11), indicating the presence of at least two intermediate states.
The sign of the fluorescence intensity changes varied between different steps. A first process
involved a fluorescence increase, as expected if the NBD reporter transitioned into a more
hydrophobic environment. However, the second process involved an opposite intensity change.
This observation suggests that the Ct of ATRAM, where NBD is conjugated, temporarily explored
a less hydrophobic environment. The final step again involved a transition into a more hydrophobic
environment, likely corresponding to the final formation of the transmembrane state. A similar
scenario was observed for the pHLIP peptide, a monomeric pH-sensitive peptide that undergoes
membrane insertion at acidic pH (110, 208). These observations suggest that pH-triggered peptides
might contort into the membrane exploring different conformations before adopting the final
transmembrane state (186). Interesting insights were obtained when the stopped-flow experiment
was repeated at different peptide to lipid molar ratios, which allowed us to study the effect of a
change in peptide density on the surface of the bilayer. We observed that the first process was
significantly faster at low peptide densities (600:1 molar lipid-to-peptide ratio). The other two
processes did not show a dependency on the peptide density (Figure 10B). However, the
unambiguous identification of each process is challenging, in part because we cannot rule out that
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other folding steps occur within the dead time of the instrument (first ~5 ms). Nevertheless, we
can hypothesize that the first step should correspond to ATRAM lying at or close to the membrane
surface. If this is correct, the dependency on peptide density would suggest that in the
concentration range we studied, there was a change in the oligomerization state of surfaceadsorbed ATRAM. When larger oligomers are present on the membrane, this would result in a
slower membrane insertion, probably because peptide-peptide interactions compete with peptidelipid interactions.
To further probe ATRAM oligomerization, we studied if the concentration of ATRAM on the
membrane surface could alter the permeability of the bilayer using an SRB leakage assay. We
observed that leakage occurred at both neutral and acidic pH. The degree of leakage depended in
both cases on the concentration of ATRAM (Figure 12A). This observation agrees with ATRAM
forming oligomers both in the membrane-adsorbed and transmembrane states. In a recent study on
aggregation of the antimicrobial peptide magainin II, Zou and colleagues found that cell
membranes were disrupted less by large peptide aggregates when compared to smaller aggregates
(209). The authors propose that magainin has to overcome a high self-interaction energy before
the peptide interacts with a lipid membrane. A similar behavior is proposed for ATRAM. We
observed that leakage did not level off or continue to increase at ATRAM concentrations higher
than 0.5 μM, but it resulted in a decrease in POPC vesicle disruption (Figure 12B). Notably, 0.5
μM is also the concentration where Wyatt et al. observed a break in the dose-dependency of
ATRAM drug delivery in cancer cells (181). The decreased in leakage shown in Figure 12B might
explain this observation, linking it to a change in ATRAM oligomerization that reduces the efficacy of drug delivery.
We previously reported that ATRAM had minimal effect on membrane leakage of a different
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fluorescent reporter, calcein (100). However, in light of our current understanding of ATRAM,
that study was not comprehensive enough, since it was only performed at pH 8. While the leakage
results yield information on the oligomerization of ATRAM, the destabilization ATRAM induces
in the lipid bilayer is not enough to cause cell toxicity, as shown by two different reports (100).
While we do not completely understand why ATRAM promotes more efficient leakage of SRB
than calcein, as both molecules are similar in weight and are both anionic molecules, previous
studies have shown that SRB is more prone to leakage with another peptide system (210).
We observed that the apparent partition coefficient strongly decreased (Figure 13) at higher
peptide concentrations at both low and physiological pH. To investigate the factors underlying the
concentration dependency of the Kapp, we repeated the experiment with NBD-labeled pHLIP.
While pHLIP shows overall less affinity to bind membranes than ATRAM, at higher
concentrations pHLIP also reduced its lipid affinity. As pHLIP is a monomer in the experimental
conditions used, this indicates that oligomerization changes are not responsible for the Kapp
changes observed for ATRAM. Instead, the dependency of the Kapp value on lipid concentration
reveals that our experiments were not in infinitely dilute conditions. Thus, the pattern of specific
Kapp change we obtain is characteristic of anti-cooperative partitioning, typically observed where
electrostatic repulsion hinders lipid binding at high peptide concentrations. This is not surprising
since both ATRAM and pHLIP have a strong negative charge (-5 and -6, respectively) in their
deprotonated peripheral state (188). For the pH 4 experiments, the peptides were incubated with
POPC at pH 8 before acidification. The accumulation of negatively charged glutamates might
result in electrostatic repulsion that carries into the electrically neutral transmembrane state.
Overall, our results suggest that ATRAM forms oligomers of different sizes at different
membrane densities. The smaller oligomers formed at lower densities insert faster into the
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membrane (Figure 10), display significantly higher membrane affinity (Figure 13) and disrupt the
membrane to a greater extent (Figure 12) than the larger oligomers. With the increased
intermolecular interaction of ATRAM, there would be a higher energy cost for the peptide to
interact with the membrane, which would slow down the initial phase of membrane insertion and
reduce POPC affinity. However, both oligomer sizes show similar pH-dependency of membrane
of insertion (Fig. S5), suggesting that the glutamate residues that control the insertion are in similar
environments (211).
Our mice data showed that ATRAM accumulates in blood-rich organs (liver and heart) (Figure
18). Additionally, administration of the peptide did not adversely affect the test animals (data not
shown). The biodistribution and SPECT/CT imaging data showed retention of radioactivity after
4 hours in the heart and liver, indicating distribution throughout the circulatory system (Figure 18).
The radioactivity of

125

I was still detectable in organs after four hours, which is longer than for

other peptides of comparable molecular weight (182, 200, 212, 213). We also observed that
ATRAM was resistant to proteolytic degradation in FBS (Figure 20). Taken together, our data
indicate that ATRAM might avoid some of the biggest challenges for therapeutic peptides, as it
did not undergo quick proteolysis or clearance. A possible explanation for this phenomenon is that
ATRAM is transported by a blood component. In fact, strategies have been explored to prolong
the half-life of peptides by increasing their affinity to serum proteins, including conjugating
peptides to ligands, such as PEG and fatty acids, (99, 182, 189, 214-216). Many hydrophobic
molecules, such as fatty acids, cholesterol (97, 217), and hydrophobic therapeutic molecules (217221) are transported in the blood by binding to serum albumin, which prolongs their circulation
time. Indeed, increasing albumin affinity is a common approach used to elongate the circulation
half-life of biomolecules, including peptides (97, 214, 215). Studies have confirmed that peptides
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modified with fatty acids, such as liraglutide and insulin detemir, bind to serum albumin, and as a
result have a prolonged circulation half-life compared to their non-modified counterparts (97, 215).
The in vitro data shown in Figure 16A show that ATRAM binds to human serum albumin,
suggesting that it uses this protein as a carrier in the blood stream, thereby explaining the long
circulation time observed. The binding affinity (KD = 1.13 ± 0.37 μM) is slightly higher compared
to a clinically used peptide, insulin detemir (4.16 μM) and other currently used drugs(97, 222). For
example, phenylbutazone, warfarin, and penicillin G bind albumin with dissociation constants
ranging from 1.4 μM (phenylbutazone) to 833 μM (penicillin G) (219-221). However, a binding
affinity in the micromolar scale is generally considered weak binding (223). In our case, this could
be beneficial, since too high of an affinity would preclude ATRAM unbinding HSA to target the
membrane of cancerous cells. We devised an in vitro assay to study if this transfer could occur.
We observed NBD intensity (Figure 16C) and anisotropy Figure 16D) changes, indicating that
ATRAM interacted with lipid membranes after pre-incubation with serum albumin. However, the
partitioning away from HSA into liposomes was not complete as expected from the HSA affinity.
Specifically, at neutral pH the lipid affinity of ATRAM is lower (∆G= -7.7 kcal/mol) than for HSA
(∆G= -8.1 kcal/mol), indicating that ATRAM favors HSA. Furthermore, it has been shown before
that HSA interacts with lipids (224-226). This raises the possibility that ATRAM might be directly
transferred from HSA to POPC, forming a ternary complex under the experimental conditions of
Figure 16C-D. Based on the low affinity of HSA to DMPC lipid vesicles (KD = 6.7 mM), only
~3.5% of HSA would be bound to the lipid vesicles (227). As a result, we expect that ATRAM
must be in solution before binding to lipid vesicles.
In the experimental conditions of Figure 16C-D, we worked with 4.2 x 1014 HSA molecules,
and a significantly larger number of POPC molecules, 2.1 x 1016, which could be erroneously
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interpreted as a larger affinity for HSA than POPC. However, the interaction of a peptide with
lipids should not be considered as a chemical equilibrium. Instead, it is more appropriate to
consider the interaction with the whole liposome surface (188). Based on the size of the liposome
and the POPC area per lipid, we calculated that in our experimental conditions, the number of
POPC liposomes was only 2.6 x 1011, a number significantly smaller than the number of HSA
molecules. Within the limitations of our in vitro conditions, we consider the excess of HSA over
the bilayer surface might not be too far away from the situation an HSA-bound ATRAM faces in
the interior of a vein or capillary, where it would slowly partition into cells. Our results suggest
that ATRAM could use HSA as a carrier and protector to travel through the bloodstream. At this
point, ATRAM can potentially unbind HSA to migrate into the plasma membrane of cancer cells.
Here we start to unravel the molecular mechanism ATRAM uses to target tumors. Achieving
this ambitious goal requires understanding not only the mechanism of specific insertion in acidic
membranes, but also the processes that allow for satisfactory biodistribution. However, in order to
make ATRAM a strong therapeutic candidate, other key parameters need to be determined. To
understand the insertion mechanism of ATRAM, the different oligomerization states of the peptide
should be further characterized. We hypothesize that the reason ATRAM can assemble into
different oligomers might be the presence of several GxxxG motifs, which often promote selfassembly of transmembrane domains (228, 229).
To advance the field of therapeutic peptides, the properties of targeted peptides, such as
ATRAM, need to be further understood. This is required to optimize some off-target localization
and the pH profile of ATRAM, which are currently under investigation in our laboratory. Here,
we were able to gain new biophysical insights into the pH-dependent membrane interaction of
ATRAM. We also showed that ATRAM can deliver PEGylated liposomes to breast cancer cells
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in a pH-dependent fashion. We hypothesize ATRAM can target to the acidic microenvironment of
tumors a wide range of nanoparticles, with probably the exception of positively charged
nanoparticles, which might stablish deleterious electrostatic interactions with the charged
glutamates in ATRAM. Furthermore, we also discovered that ATRAM interacts with a plasma
protein, serum albumin, which might explain its promising biodistribution in mice. Different types
of blood proteins bind to the surface of nanoparticles, forming a so-called protein corona (230).
The protein corona is an important determinant of the specificity and efficiency for the uptake of
nanoparticles. Our results strongly suggest that ATRAM-decorated nanoparticles will contain
albumin in the inner layers of the corona. This might be a desirable property, since the ATRAMalbumin affinity is weak, and this might preclude the formation of a stable “hard” corona (231).
Overall, our studies provide new insights necessary to develop ATRAM for direct targeting of
drugs to cells with an altered pH environment, such as tumors.
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Chapter IV. The effect of phosphatidylserine on a pH-responsive peptide
is compounded by its non-inserting end
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4.1. Abstract
The acidity triggered rational membrane (ATRAM) peptide was designed to target acidic diseases
such as cancer. The acidic environment of tumors drives the protonation of the glutamic acids of
the peptide, leading to the insertion of ATRAM into the lipid membrane with its C-terminus. The
cell membrane contains a variety of lipids. Compared to healthy cells, cancerous cells have the
negatively charged phospholipid, phosphatidylserine (PS), exposed on the outer leaflet of their
plasma membranes. Here we use a reconstituted vesicle system to explore how phosphatidylserine
influences the interaction of ATRAM with the plasma membrane of cancer cells. We observed
that modifying the sequence of ATRAM at the N-terminus affected the lipid-peptide interactions
further. The two new variants, K2-ATRAM and Y-ATRAM, displayed opposite behaviors in the
effects of phosphatidylserine on the membrane insertion pK and lipid partitioning. For all three
peptides, membrane leakage was reduced in the presence of the negatively charged lipids. Our data
indicates that the effect of PS on the insertion pK is not only of electrostatic nature, but more
complex than that. Here we try to understand how small changes to a peptide sequence can affect
how the peptide will interact with a membrane to further the design of a therapeutic peptide that
can target acidic environs of diseased cells.
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4.2. Introduction
Efficacious targeting of specific molecular markers in cancerous tumors is limited by tumor
heterogeneity and resistance acquired due to rapid mutation (232). Therefore, it can be
advantageous to target instead an intrinsic tumor property, such as the extracellular acidity (233).
Cancer cells preferentially metabolize glucose in the presence of oxygen (Warburg effect),
resulting in an increase amount of secreted lactic acid (234). Combined with poor tumor perfusion,
this leads to the accumulation of acidic metabolites and a reduction in the pH of extracellular
matrix (33). We developed the highly soluble acidity triggered rational membrane (ATRAM)
peptide to target the acidic extracellular environment of tumors(100, 181). Biophysical and cellular
experiments have shown that the membrane interaction of this highly soluble peptide is pHdependent. At physiological pH, ATRAM partitions to lipid membranes, but at acidic pH it inserts
into the membrane as an alpha helix. ATRAM has been able to deliver a cell-impermeable toxin
into HeLa cells, as well as efficiently target solid tumors (181). The insertion pK of ATRAM in
POPC vesicles was previously determined to be 6.5 (100). This pH is at the lower limit of tumor
extracellular acidity (91, 235). To address the need to target mildly acidic tumors, here we worked
to tune the tumor-targeting properties by designing two variants with N-terminal modifications.
The effect of positively charged amino acids and aromatic amino acids on the insertion of ATRAM
was studied.
Previous biophysical experiments studying the membrane interaction of ATRAM have been
limited to use the phospholipid phosphatidylcholine (PC) headgroups in single component
systems, more specifically 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) (100, 181).
However, the lipid bilayer of the cell membrane is more complex as both leaflets contains a variety
of lipids (236). We are particularly interested in one specific phospholipid, phosphatidylserine
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(PS). PS represents approximately 10% of the phospholipids in the plasma membrane and remains
sequestered in the inner leaflet of healthy cells (237). Compared to healthy cells that have
asymmetric bilayers, cancerous cells can lose their asymmetry and as a result have
phosphatidylserine on both leaflets of their plasma membranes (238, 239). Unlike PC lipids that
contain a zwitterionic head group, PS is a negatively charged phospholipid. ATRAM has a
negative net charge at physiological pH; therefore, electrostatic repulsion can emerge between the
negative charges of the peptide and the membrane of tumor cells.
Here we show that the insertion pK of ATRAM did not change with increasing concentrations
of the phosphatidylserine, but how the peptide interacted with the membrane was altered.
Furthermore, the N-terminal modified variants interacted with the lipid membrane differently from
ATRAM, though they both maintained their acidity-targeting properties. We looked into
electrostatic interactions as a possible explanation for these different behaviors by performing
additional experiments in the presence of NaCl. By understanding how negatively charged lipids
affect the insertion of ATRAM into membranes, we can continue to rationally fine-tuning the
sequence of ATRAM and increase its efficacy to insert into cancer cell membranes.

4.3. Experimental Procedures
Preparation of liposomes. Stocks of POPC and POPS (Avanti Polar Lipids, Inc., Alabaster, AL)
were prepared in chloroform. Lipids were dried flushing with argon gas and placed under a vacuum
overnight to create lipid films. The resulting dried lipid films were hydrated with 10 mM sodium
phosphate (pH 8.0) and extruded with a Mini-Extruder (Avanti Polar Lipids, Inc., Alabaster, AL)
through 100 nm polycarbonate filters (Whatman, Maidstone, United Kingdom) to create large
unilamellar vesicles (LUVs).
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Peptide labeling. C-terminal Cys ATRAM and K2-ATRAM variants (Table 4) were conjugated
to the environmentally sensitive dye NBD, [N, N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa1,3-diazol-4-yl)ethylenediamine] (Thermo Fisher Scientific, Inc., Waltham, MA).

Y-ATRAM

(Table 4) was labeled at the N-terminus with succinimidyl 6-n-7-nitrobenz-2-oxa-1,3-diazol-4-yl
amino hexanoate (NBD-X SE; Anaspec, Fremont, CA). Free NBD dye was removed by gel
filtration using a PD-10 column (GE Healthcare Life Sciences, Marlborough, MA), while labeled
and unlabeled peptide were separated by reverse-phase HPLC (Agilent, Santa Clara, CA). The
purity of the conjugations was confirmed by MALDI-TOF (Bruker, Billerica, MA).
pK determination. Peptides were prepared in 10 mM sodium phosphate pH 8.0 and incubated
with vesicles POPC or POPC/POPS (molar ratio ranging between 95/5 and 80/20). After a 1-hour
incubation at room temperature, the samples were pH-corrected with 100 mM buffers (sodium
acetate, MES, HEPES, or sodium phosphate). The final pH was measured after obtaining the
fluorescence spectra. The molar lipid-to-peptide ratio was 200:1 with a final peptide concentration
of 1 μM. The lipid-to-peptide ratio was changed to 150:1 for experiments studying the effect of
salt due to the scattering effect of sodium chloride on the lipid vesicles. The final sodium chloride
concentration in those experiments was 150 mM. Fluorescence emission spectra was measured on
a QuantaMaster fluorometer (Photon Technology International, Edison, NJ) with λex = 280 nm and
λem = 310-400 nm. The emission polarizer was set to 90°, and the excitation polarizer was set to 0°
to reduce the light scattering effect of liposomes (107). Appropriate lipid backgrounds were
subtracted. Fluorescence intensities at 335 nm (F) were fitted to determine the pKFI, using:
𝐹𝐹 =

𝐹𝐹𝑎𝑎 +𝐹𝐹𝑏𝑏 ∗10𝑚𝑚(𝑝𝑝𝑝𝑝−𝑝𝑝K𝐹𝐹𝐹𝐹 )
1−10𝑚𝑚�𝑝𝑝𝑝𝑝−𝑝𝑝K𝐹𝐹𝐹𝐹 �
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(8),

Table 4. Sequences of the ATRAM peptide and the variants
Peptide

Sequence

ATRAM

GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN

K2-ATRAM

GKAGKAGLLGLEGLLGLPLGLLEGLWLGLELEGN

Y-ATRAM

GYAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN

Residues in red are the N-terminal modifications, while residues in blue are replaced with Cys
for conjugation. E12 and W26 are bolded to aid in the Discussion.
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where Fa is the acidic baseline, Fb is the basic baseline, m is the slope of the transition, and pKFI is
the midpoint of the curve.
The PS50 was determined by:
𝐹𝐹𝑜𝑜 + (∆𝐹𝐹) × (𝑥𝑥 /(𝑃𝑃𝑃𝑃50 + 𝑥𝑥)) (9),

where Fo is the initial fluorescent signal, ΔF is the change in the fluorescent signal, and x is the
molar percentage of PS.
Circular dichroism. Peptides were prepared in 10 mM sodium phosphate pH 8.0 and incubated
with POPC or POPC/POPS (9/1 molar ratio) vesicles. The pH of the samples was altered with 100
mM sodium acetate pH 4 or 100 mM sodium phosphate pH 8 after a 1-hour incubation at room
temperature. The final pH was measured after measuring the spectra. The lipid-to-peptide ratio
was 200:1 with a final peptide concentration of 5 μM. Appropriate blanks were subtracted.
Measurements were performed on a Jasco J-815 spectropolarimeter (Easton, MD) at room
temperature. Raw data were transformed to mean residue ellipticity according to
[Θ] =

Θ

10𝑙𝑙𝑙𝑙𝑙𝑙

(10),

where Θ is the measured ellipticity in mdegree, l is the path length of the cuvette in cm, c is the
peptide concentration in M, and N is the number of peptide bonds.
Oriented circular dichroism. Lipid or lipid-peptide (50:1 molar ratio) films were resuspended in
methanol and added onto two circular quartz slides (Hellma Analytics, Germany). The slides were
placed under vacuum for 24 hours to evaporate the solvent. The samples on the slides were
rehydrated with 100 mM sodium acetate pH 4 for 16 hours at room temperature at 96% relative
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humidity. The slides with the samples were placed on opposite sides of the OCD cell in a manner
that would seal the cell. This ensured that the saturated K2SO4 that filled the inner cavity of the
cell would remain hydrated and constantly humidify the sample throughout the experiment. The
sample was recorded on a Jasco J-815 spectropolarimeter at room temperature. Eight 45° angle
intervals were measured to limit the artifacts caused by linear dichroism and then averaged for the
final spectrum. Data were converted into mean residue ellipticity after lipid blanks were subtracted.
The theoretical transmembrane and peripheral helix spectra was calculated as described by Wu
and colleagues (122).
NBD lipid binding assay. NBD labeled peptides were prepared in 10 mM sodium phosphate pH
8.0 and incubated with various POPC or POPC/POPS (9/1 molar ratio) concentrations at a final
peptide concentration of 0.2 or 0.5 μM. The lipid-to-peptide ratios were maintained over the two
peptide concentrations. After a 1-hour incubation at room temperature, the pH of the samples was
changed with 100 mM sodium acetate pH 4.05 or 100 mM sodium phosphate pH 7.5. Fluorescence
spectra were measured on a Cytation 5 microplate reader (BioTek Instruments, Inc., Winooski,
VT) with λex = 470 nm and λem = 520-600 nm. Fluorescence intensities at 540 nm (F) were
normalized to the highest value of each individual binding curve and were fitted with:
Kp ×[L]

F = Fo + ∆F × 55.3+Kp ×[L] (11),
where Fo is the initial fluorescence intensity, ΔF is the overall change in fluorescence signal, Kp is
the partition coefficient, [L] is the concentration of lipids, and 55.3 is the molar concentration of
water.
Sulforhodamine B leakage assay. Dequenching experiments were used to measure the release
of sulforhodamine B (SRB) from POPC or POPC/POPS (9/1 molar ratio) vesicles. The dye was
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encapsulated into large unilamellar vesicles (LUVs) by resuspending the dried lipid film with 20
mM SRB and extruded with 200 nm filters. The SRB-LUV suspensions were purified with a PD10 column. A consistent volume of peptide at different initial concentrations was added to the
SRB-LUV suspensions to extend a range of lipid-to-peptide ratios. Samples with either 10 mM
sodium phosphate pH 8 or 1.5% Triton X-100 added instead of peptide were used as controls. The
pH of the samples was adjusted with 100 mM sodium acetate pH 4.05 or maintained with 100 mM
sodium phosphate pH 7.5 after a 1-hour incubation at room temperature. The change in
fluorescence intensity was measured after an additional 1-hour incubation on a Cytation 5
microplate reader with λex = 550 nm and λem = 590 nm. SRB leakage was calculated with the
following equation:
% Leakage = 100 ×

(𝐹𝐹−𝐹𝐹𝑚𝑚𝑚𝑚𝑚𝑚 )

(𝐹𝐹𝑚𝑚𝑚𝑚𝑚𝑚 −𝐹𝐹𝑚𝑚𝑚𝑚𝑚𝑚 )

(12),

where F, Fmax, and Fmin are the measured fluorescence intensities of SRB-LUV suspensions
with peptide, Triton X-100, and buffer, respectively. A correction was applied to account for the
change in SRB fluorescence caused by Triton X-100.
The midpoint of leakage (SRB50) was determined by:
𝐿𝐿𝑜𝑜 + (∆𝐿𝐿) × (𝑥𝑥 /(𝑆𝑆𝑆𝑆𝑆𝑆50 + 𝑥𝑥)) (13),

where Lo is the initial leakage percentage, ΔL is the increase in the leakage percentage, and x is the
peptide:lipid molar ratio.
Statistical analysis. Statistical analysis on pKFI and Kp was performed using the SPSSv25 software
(IBM Analytics, Armonk, NY). Levene’s test was performed to determine the homogeneity of the
variance. Multiple comparisons tests were chosen based on the homoscedasticity (Tukey) or
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heteroscedasticity (Dunnett T3) of the data. Comparison of the pKFI values was performed using
the Tukey test, while the Kp was compared using the Dunnett T3 test. p ≤ 0.05 was considered
significant.

4.4. Results
ATRAM variants. The molecular basis of the interaction of ATRAM with lipid membranes is
poorly understood. To fill this void in knowledge we performed mutational analysis. However, so
as not to disrupt the overall membrane interaction of the peptide, we did not mutate the inserting
C-terminal end (240). Instead, we modified the N-terminus and created two variants, named K2ATRAM and Y-ATRAM (Table 4). We first performed studies at pH 8 where ATRAM is a
surface-bound peptide, and then at pH 4 where ATRAM is a transmembrane peptide (100).
Fluorescence emission and circular dichroism spectra both showed that the overall pHresponsiveness of the peptides was maintained in both POPC and POPC/POPS (molar ratio = 9/1)
lipid vesicles. For the three peptides, the maxima of the fluorescence spectra blue-shifted more
than 10 nm and was associated a large intensity increase when dropping the pH of the lipid
environment (Figure 21 and Table 5). This indicates that upon acidification the single Trp (Table
4) transitioned from a polar environment to a hydrophobic one. The CD spectra showed that the
peptides were mostly unstructured in buffer and lipid vesicles at pH 8, but they formed alpha
helices in lipid vesicles at pH 4 (Figure 22). These results were expected as the peptide pHresponsive properties are driven by the protonation of the four glutamic acid residues present in
all peptides and also because we did not alter the inserting C-terminal end.
Oriented circular dichroism (OCD) was performed to study the helical orientation of the
peptides with respect to the plane of the bilayer. If a helical peptide forms a surface-bound helix,
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Figure 21 The peptides interact with the lipid membrane in a pH dependent manner.
Representative intrinsic tryptophan fluorescence spectra of ATRAM and the variants in the
presence of POPC (A) and POPC/POPS (9/1) (B) vesicles at pH 4 (red) and pH 8 (blue).
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Table 5. Fluorescence spectral maxima of the acidic and basic baselines
ATRAM (nm)

K-ATRAM (nm)

Y-ATRAM (nm)

POPC acidic

327.3 ± 0.7

329.7 ± 1.2

324.5 ± 2.9

POPC basic

341.1 ± 2.3

342.1 ± 2.1

343.9 ± 3.6

POPC/POPS acidic

330.8 ± 0.8

320.2 ± 1.7

320.5 ± 1.9

POPC/POPS basic

350.9 ± 1.0

331.7 ± 1.8

342.7 ± 2.3
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Figure 22. The peptides changed in secondary structure in a pH dependent manner. CD
spectra of ATRAM and the variants in solution at pH 8 (black) and in the presence of POPC (A)
and POPC/POPS (9/1) (B) vesicles at pH 4 (red) and pH 8 (blue).
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the spectrum would show two clear minima at ∼205 and ∼222 nm, while the spectrum of a TM

helix would have a single broad minimum at ~225 nm. Our experimental data indicate that all
peptides adopt a TM orientation at pH 4 in both lipid compositions (Figure 23). Theoretical
oriented circular dichroism (OCD) curves in POPC vesicles were shown along the measured
curves of the peptides to highlight the orientation of the variants. The variation between the
theoretical curves of the different peptides arises from the fact that the theoretical curves depends
on the fractional helicity of the peptides (122, 241).
pK of insertion. To determine the pKFI of insertion of the ATRAM variants, we followed the
changes of the intrinsic tryptophan fluorescence intensities of the emission spectra as the pH is
decreased from pH ~8 to pH ~4 (Figure 24) (186). Compared to ATRAM (6.20 ± 0.15), the pKFI
of Y-ATRAM (6.27 ± 0.12) did not change significantly in experiments performed with POPC
vesicles. However, with K2-ATRAM, we observed a large acidic shift (5.42 ± 0.14). We studied
if similar results were observed when PS was present in the vesicles. Over a range of PS levels,
the changes in pKFI of insertion differed between the three peptides (Figure 25 and Figure 26).
ATRAM did not have a significant difference in its pKFI with the addition of PS in the lipid
vesicles. However, there was a different and opposite behavior observed for K2-ATRAM and YATRAM. The presence of PS resulted in an increase in the pKFI of K2-ATRAM and a decrease in
the pKFI of Y-ATRAM. The effect on the pKFI was seen at low concentrations of PS as the PS50
was 1.89 and 0.45 for K2-ATRAM and Y-ATRAM, respectively. The PS trend that was observed
with Y-ATRAM also occurred previously with pHLIP, a model pH-sensitive membrane peptide
(90). For pHLIP, this decrease in pKFI was due to electrostatic interactions between PS and pHLIP
as Coulombic interactions were screened with NaCl. To study whether this was also the case for
the ATRAM peptides, the pKFI was determined in the presence of 150 mM NaCl (Figure 25 and
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Figure 23. The ATRAM peptides adopt a TM conformation at low pH. (Top) Oriented circular
dichroism spectra of the peptides (black) in hydrated stacked POPC bilayers. The dark grey and
light grey lines correspond to theoretical OCD spectra for TM (dark grey) and surface-bound (light
grey) helical peptides, respectively. (Bottom) Oriented circular dichroism spectra of the variants
in hydrated stacked POPC/POPS (9/1). Theoretical curves were not generated due to uncertainties
in the amount of peptide deposited on the quartz slides.
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Figure 26). For ATRAM, the pKFI of both lipid conditions decreased compared to the values
obtained in the absence of NaCl. This was also observed for Y-ATRAM; furthermore, the
difference in pKFI values between the two lipid conditions was no longer observed. However, pKFI
of K2-ATRAM behaved differently. Specifically, it only decreased in liposomes with POPS but
not for POPC only liposomes. Similar to Y-ATRAM, the difference in pKFI between POPC and
POPC/POPS vesicles was lost in the presence of NaCl. Furthermore, the pKFI in the presence of
NaCl was still different than the other two peptides. Titrations in the presence of NaCl were
performed with a lipid-to-peptide ratio of 150:1 instead of 200:1 due to scattering effect of the
lipid. There was no significant difference in the insertion pK of ATRAM in POPC vesicles at 150:1
and 200:1 lipid-to-peptide ratios in the presence of 150 mM NaCl (Figure 27). To unravel the
causes for the different effect of PS on the three ATRAM peptides, we performed additional
studies.
Partition coefficient. We have previously reported that the POPC affinity of ATRAM is higher
at acidic pH than neutral pH as a consequence of the increased hydrophobicity resulting from the
protonation of the glutamic acids (240). This was also observed for the ATRAM variants (Figure
28). Interestingly, the effect of PS on the partition coefficient at acidic pH mirrors the trends seen
in the pKFI as the Kp did not change for ATRAM, increased for K2-ATRAM and decreased for YATRAM. Previously, the binding of ATRAM to the lipid membrane was considered nonideal as
the partition coefficient depended on the peptide concentration, and thus the Kp is in reality an
apparent Kp (240). Here we show that this was also true for all the variants in both lipid
composition as we repeated the binding assay at a lower peptide concentration (Figure 29 and
Figure 30). This suggests that they all interact with the membrane in a similar fashion.
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Figure 27. Overlay of pH titration of ATRAM in POPC vesicles at 150:1 (open symbols) and
200:1 (closed symbols) in presence of 150mM NaCl.
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Leakage. ATRAM oligomerizes on the membrane of POPC vesicles (100). Membrane disruption
often results from peptide oligomerization (242). Next, we studied the effect of the peptides on
leakage to gain insight into peptide oligomerization. We performed SRB leakage assay in POPC
and POP/POPS (molar ratio = 9/1) vesicles (Figure 31), where SRB dequenching occurs as it is
released. ATRAM and Y-ATRAM seemed to disrupt the POPC membrane similarly. ATRAM
observed similar leakage at low and neutral pH, but the leakage midpoint (SRB50) saw a three-fold
decrease at low pH compared to neutral pH (0.06 vs. 0.19, respectively). This trend was also
observed for Y-ATRAM (SRB50 = 0.03 vs. 0.10). However, K2-ATRAM had the least amount of
leakage in the surface-bound state and a large difference in amount of leakage between the two
states. Similar to ATRAM, the SRB50 was lower for the inserted state (0.17) compared to the
surface-bound one (0.72). Unlike ATRAM and Y-ATRAM, the highest amount of peptide
concentrations was required to acquire maximum leakage. With the presence of PS in the vesicles,
there was less leakage observed with K-ATRAM. The main difference for ATRAM and YATRAM was that they lost their property of needing lower peptide concentrations for maximum
leakage. The SRB50 increased with the addition of PS for all three peptides in both pH 4 and 7.5
(0.25, 0.17; 0.43, 1.36; 0.84, and 0.81 for ATRAM, K2-ATRAM, and Y-ATRAM, respectively).

4.5. Discussion
In this work, we studied how ATRAM was affected by the presence of PS in the membrane.
We also developed two N-terminal variants. Fluorescence and circular dichroism confirmed that
the peptides maintained their pH-sensitive properties. Furthermore, OCD experiments showed that
the peptide acquired a TM confirmation at low pH.

The OCD spectra of the peptides in

POPC/POPS had lower signal than those in POPC. A possible explanation is that that the negative
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Figure 31. Membrane leakage studies. Dequenching of sulforhodamine B (SRB) encapsulated
in POPC (A) and POPC/POPS (9/1) (B) vesicles was monitored after the addition of peptide
(0.0025− 1 mol %) at pH 7.5 (blue) and pH 4 (red/orange). Complete leakage was achieved on
addition of Triton X-100. Mean values are shown ± S.D. (n = 4).
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charges of PS repelled each other (243), making it harder for lipid bilayers to stack on top of each
other on the quartz slide, reducing the overall signal.
Here, the pKFI of ATRAM was determined to be 6.2. However, the previously published
insertion pK value of ATRAM in POPC was 6.5 (100). This value was determined by following
the shift of the fluorescence spectral maximum over a pH range, while the new value was
determined by following the changes of the intrinsic tryptophan fluorescence intensities. It has
previously been shown for pHLIP that different methods of spectral analysis resulted in different
pK values as each method reported on a different intermediate of the peptide’s transition into the
membrane (186). Previous stopped-flow fluorescence data showed that ATRAM undergoes at
least three states when transitioning from the peripheral state to the TM state (240). This result
suggests that the different pK values of ATRAM might be associated with a different
conformational intermediate.
The decrease in insertion pK of K2-ATRAM in POPC vesicles compared to ATRAM and YATRAM indicates that there was a need for more acid for the peptide to be able to insert as a result
of the addition of the two basic residues. The interaction with the membrane defining the pKFI was
electrostatic for ATRAM and Y-ATRAM, but this was not the case with K2-ATRAM since there
is no change in pKFI with the addition of NaCl. As tumor cells have PS exposed on the outer leaflet
of their cell membranes, we studied the effect of PS on the interactions of the peptides with
membranes. Interestingly, with the addition of PS in the vesicles, the two variants had opposite
trends. The increase in K2-ATRAM’s insertion pKFI is expected to resort from to favorable
interactions with the negative charge of PS. This time the addition of NaCl also resulted in a
decrease in pKFI, indicating that the main interaction with PS are electrostatic for all peptides.
However, the NaCl experiments were performed at a lower lipid-to-peptide ratio (150:1 vs. 200:1).
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While the pKFI did not differ for these two ratios (Figure 27), we cannot rule out that any effects
from working at non-saturating conditions at pH 7.5, particularly for Y-ATRAM (Figure 30).
Unlike Y-ATRAM, the pKFI of ATRAM and K2-ATRAM observed a different trend compared
to pHLIP with the addition of PS. This result indicates that pKFI is not controlled by a simple
electrostatic process (90). For pHLIP, it is believed that the decrease in membrane insertion pK for
PS suggested that the protonatable residues are more hydrated (90). This would have resulted from
the peptide having a shallower position on the membrane surface due to the negatively charged
lipids and exposing the sidechains of the protonatable residues to the aqueous environment. The
spectral maximum of the C-terminal Trp is sensitive to hydration, and then it reports the membrane
depth (Table 5). The Trp is surrounded by three of the four Glu. However, we did not observe a
good correlation between the Trp hydration and the pKFI. Here we hypothesize that the glutamate
at position 12 (E12) affected the insertion pKFI that resulted from the modifications at the Nterminus. E12 is the glutamate that is closest to the N-terminus but also the furthest from the Trp.
Integration of the data of Table 5 and Figure 25A allows us to propose a working model (Figure
32). W26 and E12 of ATRAM maintained a similar position on POPC membranes, resulting in no
changes in the pKFI. The polar lysines of K2-ATRAM does not favorably interact with the
hydrophobic membrane, thus it pulls the N-terminal region, including E12, away from the
membrane, resulting in a much lower pKFI (211). As ATRAM did not observe changes in its pKFI
and spectral maximum with the presence of POPS, it is assumed that E12 and W26 maintained a
similar position in both POPC and POPC/POPS membranes. For K2-ATRAM, the N-terminal
interacted with the negative charges of PS due to the positive charges on the lysines. This brought
E12 closer to the membrane, thus increasing the pKFI in the presence of PS. Y-ATRAM observed
a similar trend as pHLIP. The side chains of the aromatic amino acids, such as Tyr, can provide a
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Figure 32. Schematic of the surface-bound state of the ATRAM peptides. The proposed
locations of E12 and W26 residues are shown in green and blue, respectively, while the modified
residues at the N-terminal are marked in pink. The two Lys are represented as a single sphere. The
headgroup of PS is highlighted in black.
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surface of negative electrostatic potential that binds to cations through electrostatic interactions
(244). In our case, we can hypothesize that the interaction of the tyrosine and the negatively
charged PS resulted in an electrostatic repulsion. This led to E12 be more exposed to the aqueous
environment and decreasing the insertion pKFI in the presence of PS. Figure 32 only shows the
proposed location of E12 and W26 in the surface-bound state as we do not assume that the TM
state affected the changes in the pKFI. The Kp data at acidic pH correlate with the pKFI (Figure 25
and Figure 26). The increase in affinity in the presence of POPS that was observed with K2ATRAM was probably due to favorable electrostatic interactions of the positively charged Lys and
the negatively charged PS, while the opposite of seen with Y-ATRAM. The surface of negative
electrostatic potential of Tyr probably resulted in non-favorable interactions with the negatively
charged lipids and thus decreasing the binding affinity.
While the peptides resulted in the leakage of SRB, we have shown before that the disruptions
caused by ATRAM are not significant to cause cell death in cultured cells (100). SRB is a relatively
small molecule (MW = 558.6 Da), indicating that the effects on the lipid membrane are small.
Moreover, we previously reported that ATRAM had little effect on membrane leakage of calcein,
while SRB observed a higher amount of leakage compared to calcein (100, 240). This corresponds
to a previous report that SRB is more disposed to leakage with another peptide system (210). We
have previously proposed that the concentration dependent leakage resulted from the need of
ATRAM to overcome a high self-interaction energy before interacting with the POPC membrane
as ATRAM oligomerizes (240). A similar explanation is proposed for Y-ATRAM. However, this
property was lost in POPC/POPS liposomes and in K2-ATRAM.

The data suggest that

oligomerization changes do not explain the differences.
The pK of insertion of the variants still remained lower than the pH of the extracellular matrix
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of tumor cells (pH 6.4–7.0) (36, 233), though the local pH at the membrane surface that would
drive the peptide insertion is significantly more acidic that the bulk microenvironment (177, 178).
However, K2-ATRAM did observe a higher affinity to membranes with PS. Furthermore, the
presence of small amounts of PS rapidly increases the pKFI. These characteristics are important as
it suggests that K2-ATRAM might display an increased specificity for tumor cells. Y-ATRAM is
expected to be the least effective cancer targeting peptide variant since its pKFI decreases and its
partition coefficient is much lower when exposed to PS headgroups compared to POPC only
vesicles. We will use the observations from these experiments to fine-tune the sequence of
ATRAM as a specific therapeutic agent for acidic diseases such as solid tumors.
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Chapter V. Conclusions and Future Directions
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5.1. Conclusions
Currently, therapeutic peptides are in high demand as they can improve the low accumulation
of nanoparticles and drugs at tumor sites (157). By attaching the nanoparticle or drug to a peptide,
the peptide can improve their stability and tumor targeting specificity and efficiency. As peptides
are made up of amino acids, their properties can be easily altered to make it highly specific to its
target. Many different tumor targeting peptides have been designed to target the properties of
tumor cells, such as increased cell receptors or the presence of negatively charged lipids on the
outer leaflet of the plasma membrane. In these cases, the sequence of the peptide would include a
specific motif to bind to the cell receptor or a high number of positive charged amino acids to
interact with the negatively charged lipid headgroups (21, 57). Another cancer cell property that
can be targeted is the acidic extracellular matrix as cancer cells have an extracellular pH that is
0.5-1 pH unit lower than healthy cells (36). As glutamates, aspartates, and histidines have
sidechains that are protonatable, including these amino acids into the peptide sequence can provide
it pH-sensitive properties. In this work, we have rationally designed and characterized a novel
class of pH-responsive peptides, ATRAM.
Biophysical and cellular experiments have been performed to show that the acidity-triggered
rational membrane peptide can exist as a surface-bound or transmembrane peptide depending on
the pH of the lipid environment. The highly soluble peptide partitions onto the membrane as a
primarily random coil structure at physiology pH and will fold into the membrane as a TM α-helix
at acidic conditions. This structural change stems from the protonation of the four glutamic acids
present in the peptide sequence. ATRAM also maintained its pH-responsiveness in two different
cultured cancer cell lines. What makes ATRAM stand out in the diverse pH-sensitive peptide
group is that ATRAM was not designed to and does not induce membrane pore formation.
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Furthermore, its pK of insertion into lipid vesicles is higher than the other pH-sensitive peptides
and closer to the range on mildly acidic tumors.
We furthered the understanding of ATRAM’s insertion into lipid vesicles with fluorescence
microscopy and more biophysical experiments. It was determined that the peptide inserts into the
membrane in a primarily unidirectionally manner with its C-terminus across the plasma membrane.
Moreover, this data confirmed that ATRAM is able to deliver large molecules to the cell membrane
in a pH-dependent manner. We have also shown with kinetics experiments that the first observable
intermediate formed when the peptide transitions from surface-bound to TM state is dependent on
the peptide density on the surface of the bilayer while the other two transitions did not. The slower
occurrence of the intermediate is believed to be related to the oligomerization state of ATRAM.
Leakage and binding studies confirmed that the membrane interactions of the peptide are
oligomerization and concentration dependent. Furthermore, our data showed that the interaction
of ATRAM with human serum albumin is potentially the reason why the peptide exhibits an
extended bloodstream circulation in vivo. The abundant protein probably shielded the peptide from
proteases once injected into the bloodstream. The fact that ATRAM was able to avoid immediate
degradation leverages its ability to be used as a therapeutic molecule as proteolysis is a common
downfall of peptides (245).
ATRAM has only been studied interacting with membranes composed of PC phospholipids.
However, the plasma membrane is a diverse system that contains a variety of additional
phospholipid head groups, including PS. A normal cell actively keeps PS in the inner leaflet and
away from the extracellular environment. However, this lipid asymmetry is lost in cancerous cells
(239). ATRAM’s interaction with the lipid membranes changed with the addition of the negatively
charged lipid. While the pK of insertion did not change, the binding and the membrane disruption
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effects were affected. Moreover, N-terminal modification were made to generate two new variants,
K2-ATRAM and Y-ATRAM. Unlike ATRAM, these two variants did observe opposite trends in
the insertion pK in addition to changes to their lipid binding and membrane disruption effects. We
hypothesize that the differences on the insertion pK resulted from changes to the environment of
E12, the glutamate closest to the N-terminal. This work shows that with the right modifications,
an ATRAM variant can effectively target tumors without excluding mildly acidic tumors.
Overall, my work emphasizes the ability of the ATRAM peptide class to be established as a
therapeutic molecule for cancer and other diseases that lead to acidic tissues. The targeting abilities
can be enhanced by continuing to rationally fine-tune the sequence of ATRAM.

5.2. Future Directions
We have only started to study the potential of ATRAM. Many more variants can be created and
investigated for either lipid-protein interaction studies or therapeutic studies. The three variants
studied here behaved differently in a more intricate lipid system. It would be interesting to
continue to study these properties and see how single modifications can affect lipid-protein
interactions or even how it can affect self-interactions. Furthermore, these peptides will currently
target moderately acidic tumors, which is not the most ideal in terms of cancer targeted therapy as
they would exclude mildly acid tumors and early stage tumors (36). A study has shown that
replacing a glutamic acid into the ATRAM sequence will lower the insertion pK (data not shown).
Perhaps by removing a glutamate or by moving one up or down the sequence can change the
insertion pK to a desired range in the presence of PS, while maintaining its ability to avoid
proteolysis in blood.
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